Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
PROTAC, which exploit the ubiquitin-proteasome pathway to specifically degrade target proteins. PROTACs not only solve the problem of undruggability but they also have other advantages compared to traditional drug targeting strategies.
-
PROTAC — Target Selection and Design
2022-07-08
A PROTAC molecule consists of three components: a target protein binding ligand, an E3 ligase ligand, and a linker connecting these two moieties. Here, we will discuss the conventional approaches for the rational design of PROTAC molecules. -
BacPROTACs is composed of a POI ligand, a chemical linker and a ClpCNTD anchor. BacPROTACs can induce in vitro and in vivo degradation of non-eukaryotic proteins in bacteria without the ubiquitin proteasome system.
-
RNA therapeutics have changed the landscape of drug development, which possess broader spectrum of drug targets, simplicity and efficiency in development and manufacturing.In this article, we will discuss the underlying mechanisms of RNA-based drugs on the market or in clinical stages.
-
Autophagy, derived from the Greek meaning "eating of self", plays an indispensable role in maintaining homeostasis. p27 is an inhibitor of cyclin CDKs, but how p27 regulates autophagy remains unknown. This article will cover the mechanism of autophagy and p27-related cell cycle regulation.
-
AlphaFold2 can predict disease-related protein structures at low cost, and then find potential drugs for these diseases through drug repositioning, virtual screening, and other methods. ZINC is a public database summarizing information about billions of compounds. AlphaFold2 + ZINC20 speeds up the virtual screening process and improves the computing speed.
-
CMA (chaperone-mediated autophagy) plays an essential role in maintaining neuronal protein stability and preventing neurodegeneration. In this article, we will comprehensively clarify the role of CMA in the occurrence and development of neurodegenerative diseases.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
As powerful pain relievers, the opioids morphine and fentanyl have been "checked" by their side effects (listed as controlled substances). How to reduce its side effects? What is its mechanism? This research will explore its mechanism.
-
Understanding the mechanism of aging not only has guiding significance for prolonging human life but also has important clinical significance for the prevention and treatment of diseases in the elderly population , thus, improving their life quality and well-being.
-
The latest study of Cell magazine "Neural mechanism underlying depressive-like state associated with social status loss" considers social factors as a breakthrough point. It has been found that the downward transition of social status induces depression-like behavior in mice whereas improves the depressive state by restoring their social environment.
-
PROTAC - Design Strategy for Targeting
2023-04-23
Protein degradation targeting chimera (PROTAC) is a technology that uses the ubiquitin proteasome pathway to silent target protein. However, PROTAC still has problems such as solubility, membrane permeability, and selectivity. In this article, we have summarized three strategies for optimization: light-controlled linker, PAC molecule, and specific E3 ligase. -
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Mitophagy:Mechanisms and Detection
2023-05-25
About 60 years ago, Christian de Duve first used the term "autophagy" to describe his observation of the degradation of mitochondria and other intracellular structures in lysosomes of rat liver. Over the years, autophagy has remained a beloved topic of research by the National Natural Science Foundation of China (NSFC).Today, let's talk about mitochondrial autophagy. -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
How to Perform Western Blot?
2023-07-13
Western blot is one of the most frequently performed experiments in molecular biology, biochemistry and immunology. This article describes in detail how to do WB. -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
SPR, which stands for Surface Plasmon Resonance, essentially works by detecting the interaction between ligands and analytes on a biosensor chip. This in turn allows us to probe the properties and structure of substances. With this technology, we can analyze molecules, proteins, DNA, and various organic and inorganic substances in samples in real-time with precision.
-
Science | A "new" mechanism for non-ubiquitinated Midnolin-proteasomal degradation pathway
2024-04-26
“ubiquitin-mediated protein degradation” won the Nobel Prize in Chemistry in 2004! In fact, proteasomes degrade not only ubiquitinated proteins but also non-ubiquitinated ones. The mechanism remains shrouded in mystery. After reading this piece today, you might have a lightbulb moment! -
Common Questions and Solutions for WB
2024-05-09
Come to understand the common problems and solutions of WB, and better complete the experiment! -
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
Degrade target proteins through the autophagy-lysosome pathway including LYTAC, AUTAC, and ATTEC have gained increasing attention in recent years due to their significant research potential!
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
Streptavidin-Biotin System
2024-08-03
Streptavidin strongly binding small molecule biotin is one of the most popular non-covalent coupling methods. Streptavidin can be coupled to various carriers such as magnetic beads and agarose matrix, and become a highly specific affinity medium to capture various biotin-labeled ligands. -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
Delve into the intricate networks that govern mitochondrial quality control. By examining key mechanisms such as biogenesis, mitochondrial dynamics (fission and fusion), proteolysis, and mitophagy.
-
A New Form of Cell Death: PANoptosis!
-
Advancing Chronic Kidney Disease Research with GJ103 and Lamin B1 Antibody!
-
In early January 2025, MIT Tech Review unveiled its annual list of top 10 breakthrough technologies poised to redefine the future. Among these, stem cell therapy stood out for its potential to treat diverse diseases—including neurodegenerative disorders, diabetes, cancer, and heart failure. This groundbreaking approach uses stem cells to replace damaged cells, offering hope for millions worldwide.
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
Autophagy is a fundamental process that degrades various components within the cell.
-
This article will tell you about the common methods of modeling liver disease in animal models.
-
nside cells, the homeostasis and degradation of proteins is a precisely regulated process. If proteins cannot be degraded in time, it may lead to the occurrence of various diseases such as neurodegenerative diseases and cancer. This article will tell you the process of how proteins are recognized, labeled and then degraded!
-
This article introduces some common cardiovascular disease models, inducers, modeling protocols and successful modeling cases in the research.
-
As a pivotal branch in the post - genomic era, proteomics is committed to comprehensively elucidating the types, abundances, structures, functions, and interactions of all proteins within living organisms. This article will tell you the key steps of proteomics sample preparation based on mass spectrometry. This article will tell you the key steps of proteomics sample preparation based on mass spectrometry.
-
Western blotting is a crucial and fundamental technique in life science research. It plays a significant role in exploring protein expression and function. The following article will comprehensively and thoroughly elaborate on the specific procedures and detailed key points of this experiment.
-
In protein biology, Co-IP is a powerful tool to uncover protein "social networks." But poorly performed, it easily becomes an awkward lab "meet-and-greet." Today, we discuss making Co-IP experiments elegant and efficient—so you pull down target proteins with confidence and precision.
-
Have you ever noticed that after staying up late, your appetite—especially for high-calorie foods—gets out of control? If this sounds familiar, today’s article might offer some good news.
-
A groundbreaking study in Nature Communications reveals the key mechanism behind Idiopathic Pulmonary Fibrosis and identifies an existing drug with the potential to counter it.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
For all the protein research folks out there, techniques like IP and Co-IP are no stranger, right? And of course, there's a faster and more convenient go-to tool—Protein A/G magnetic beads! In this article, let's chat about how these beads work their magic in classic experiments like IP and Co-IP.
-
Microglia– the only immune cells within the brain parenchyma. With advancements in imaging technologies, people’s understanding of microglia has shifted from being viewed as 'resting' cells to 'highly active' cells, particularly due to their dynamic processes that seem to be probing surrounding tissues and monitoring neuronal activity. This has made microglia a focal point of research in the field of neuroscience.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
Targeting the ‘Undruggable’ with PROTACs
2025-06-18
This review introduces the fundamental principles and mechanisms of PROTACs, highlights recent advances in molecular design and clinical development, and discusses emerging opportunities and remaining challenges in targeted protein degradation. -
Advances in Alzheimer's Disease Research
2025-07-16
This review summarizes current understanding of AD pathophysiology, including amyloid and tau pathology, neuroinflammation, synaptic dysfunction, and vascular abnormalities, and evaluates therapeutic strategies and experimental models. -
This review critically examines the role of the JAK-STAT pathway in immunity and autoimmune diseases, reviews current clinical applications of targeted therapies, and highlights emerging trends in autoimmune drug development.
-
This review summarizes the mechanisms of DSS-induced colitis, commonly used modeling approaches, and key considerations related to DSS molecular weight.
-
This review discusses recent progress in molecular glue technologies, illustrating how targeted protein degradation strategies enable the modulation of previously undruggable proteins.
-
This review highlights the roles of microglia in AD pathology, focusing on metabolic reprogramming and microglia-targeted therapeutic strategies.
-
Review advances in target discovery, disease modeling, and biomarkers for Parkinson’s disease, highlighting their interplay and future directions for translational research.
-
Review the mechanisms, mitochondrial regulation, disease relevance, and translational opportunities of the NLRP3–STING axis in neuroinflammation.
-
Explore the mechanisms driving immune tolerance breakdown in autoimmune diseases and emerging tolerance-restoring strategies, with a focus on IL-2-based immune modulation.
-
Review the evolution of molecular glues from serendipitous discovery to rational design, highlighting how emerging targets and advances in screening, proteomics, structural biology, and AI are expanding the druggable proteome.
-
Explore how anti-Aβ therapy is reshaping the AD treatment landscape, the rationale for multi-pathology combination strategies, and advances in biomarker-guided precision treatment.
-
Explore how mitochondrial quality control, inflammatory signaling, and metabolic–epigenetic reprogramming regulate cellular senescence and the SASP, along with strategies to restore mitochondrial homeostasis.
-
AZD5991, a macrocyclic molecule with high selectivity for Mcl-1, reduces Mcl-1 protein in AZD5991-sensitive but not in AZD5991-resistant MM cell lines.
-
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
HJB97 is a BET PROTAC inhibitor with good anti-tumor activity, and effectively blocks the degradation of BRD2, BRD3, and BRD4 proteins induced by BETd-260.
-
BR351 is a Brain Penetrant MMP Inhibitor
2019-04-05
BR351 is a brain penetrant MMP inhibitor, and a potential tool for the molecular imaging of activated MMPs with PET, with an IC50 in the nanomolar range. -
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM.
-
IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
BSJ-03-123, a Degrader with Proteome-wide Selectivity for CDK6 (PROTAC). Induces a G1 cell-cycle arrest without a measurable increase in apoptosis.
-
FT671 is a potent, non-covalent and selective USP7 inhibitor with an IC50 of 52 nM and binds to the USP7 catalytic domain with a Kd of 65 nM.
-
ZM223 is a non-sulfamide NEDD8 activating enzyme (NAE) inhibitor, with IC50 value of 100 nM in cells. ZM223 has potential to treat colon cancer.
-
ACY-1083, a Highly Selective HDAC6 Inhibitor, Reverses Chemotherapy-induced Peripheral Neuropathy
2019-05-12
ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor with an IC50 of 3 nM. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy -
MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) with a Kd of 37 nM for binding affinity to ALK. Efficacy for breast cancer and lung cancer.
-
VL285, is a Potent VHL Ligand
2019-05-24
VL285 is a Potent VHL Ligand. -
SNIPER(TACC3)-1 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway. SNIPER(TACC3)-1 induces cancer cell death.
-
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM. Potently blocks the TNF response and RIP1-dependent inflammatory cytokine MIP-1β production.
-
SJFδ, a 10-atom Linker PROTAC, Degrades p38δ
2019-06-11
SJFδ, a 10-atom Linker PROTAC, Degrades p38δ, degrades p38δwith strong capacity. SJFδ degrades p38δ with a DC50 of 46.17±9.85 nM and a Dmax of 99.41±3.31%. -
BAY-11-7082 inhibits the proliferation and induces the apoptosis of U266 cells through inhibiting NF-κB pathway. BAY 11-7082 ameliorates experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
-
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
TAS4464 is a highly potent and selective inhibitor of NEDD8 activating enzyme (NAE), with an IC50 of 0.955 nM. TAS4464 shows antitumor activity.
-
TPCA-1, a Direct Dual Inhibitor of STAT3 and NF-κB, Regresses Mutant EGFR-Associated NSCLC
2019-07-15
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding. -
ERD-308 is a highly potent PROTAC degrader of ER for ER+ breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM.
-
JG-98, an Hsp70 inhibitor, binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities.
-
MZP-55 is a selective PROTAC degrader of BRD3/4, shows no obvious effect on BRD2. MZP-55 exhibits excellent activity in cancer research.
-
dBET6 is a potent PROTAC degrader of BET, shows high affinity to BRD4(1), and possess good efficacy in T cell acute lymphoblastic leukemia activity.
-
GSK2643943A is a Novel DUB Inhibitor
2019-07-25
GSK2643943A is a novel deubiquitylating enzyme (DUB) inhibitor. GSK2643943A targets USP20/Ub-Rho and shows an IC50 of 160 nM. -
MT-802 is a potent BTK degrader based on PROTAC technology, with a DC50 of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia.
-
ACBI1 is a PROTAC Degrader of BAF Complex
2019-08-07
ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2, SMARCA4 and PBRM1, with DC50s of 6 nM, 11 nM and 32 nM in MV-4-11 cells, respectively. -
dMCL1-2 is a potent and selective degrader of myeloid cell leukemia 1 (MCL1) based on PROTAC, which binds to MCL1 with a KD of 30 nM.
-
CP-10 is a Specific PROTAC Degrader of CDK6
2019-08-25
CP-10 is a PROTAC with highly selective, specific, and remarkable CDK6 degradation (DC50=2.1 nM), which has anti-cancer activity. -
ARV-825 is a PROTAC, and acts as a potent BRD4 degrader, with Kds of 90 and 28 nM for BRD4 BD1 and BRD4 BD2, respectively.
-
GMB-475 is a PROTAC BCR-ABL1 degrader, overcomes BCR-ABL1-dependent drug resistance, targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau.
-
dBET57 is a potent and selective degrader of BRD4BD1 based on the PROTAC technology and mediates recruitment to the CRL4CRBN E3 ubiquitin ligase.
-
MD-224 is a human MDM2 degrader based on the PROTAC concept. MD-224 induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells.
-
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM.
-
CP5V is a Specific PROTAC Degrader of Cdc20
2019-11-20
CP5V is a PROTAC, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. -
PK11007 is a Mild Alkylating Agent with Anticancer Activity and induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels.
-
SD-36 is a Selective PROTAC STAT3 Degrader
2019-12-06
SD-36 is a potent, efficacious and selective PROTAC STAT3 degrader (Kd=50 nM) and achieves complete tumor regression in vivo. -
MG-277 works as a PROTAC molecular glue, inducing degradation of a translation termination factor, GSPT1 to achieve its potent anticancer activity.
-
UK 356618 is a Selective MMP-3 Inhibitor
2019-12-25
UK 356618 is a selective and potent inhibitor of MMP-3. UK 356618 exhibits potent anti-inflammatory and anti-cancer activity. -
MS432 is a first-in-class and highly selective PD0325901-based VHL-recruiting PROTAC degrader for MEK1 and MEK2 with good anti-cancer activity.
-
KB02-JQ1 is a highly potent and selective PROTAC BRD4 degrader that degrades nuclear proteins by engaging CUL4-DDB1 E3 ubiquitin ligases DCAF16.
-
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with antiangiogenic and antitumoral activity.
-
TCH-165 is a modulator of proteasome assembly, which increases 20S levels and facilitates 20S-mediated protein degradation, such as IDPs, α-syn, and tau.
-
BAY-985 is an orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 and IKKε, respectively.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
6RK73 is a covalent irreversible and specific UCHL1 inhibitor,which specifically inhibits UCHL1 activity in breast cancer.
-
Ro 90-7501, an Aβ42 fibril assembly inhibitor, inhibits PP5 in a TPR-dependent manner and has radiosensitizing effects on cervical cancer cells.
-
CCT367766, a PROTAC-based Pirin-targeting PDP, exhibits a moderate affinity for the CRBN-DDB1 complex and reveals a good affinity for Pirin and CRBN.
-
E64FC26 is a highly potent pan-style inhibitor of the protein disulfide isomerase (PDI) family with anti-myeloma activities.
-
NU1025 is a potent PARP inhibitor and potentiates the cytotoxicity of ionizing radiation drug. NU1025 has anti-cancer and neuroprotective activity.
-
TL13-112 is a PROTAC Degrader of ALK
2020-04-15
TL13-112 is a selective ALK-PROTAC degrader and inhibits ALK activity. TL13-112 is comprised of the conjugation of Ceritinib and the ligand pomalidomide . -
TL13-12 is a Selective ALK-PROTAC Degrader
2020-04-21
TL13-12 can induce receptor tyrosine kinase anaplastic lymphoma kinase degradation in non small cell lung cancer cells. PROTAC ALK degrader. -
ARCC-4 is a low-nanomolar AR degrader, and effectively degrades clinically relevant AR mutants associated with antiandrogen therapy.
-
UT-34 is a potent, selective and orally active second-generation pan-androgen receptor (AR) antagonist and degrader with anti-prostate cancer efficacy.
-
HM03 is a potent and selective HSPA5 inhibitor with anticancer activity. HSPA5 plays a key role in monitoring protein transport through the cell.
-
XZ739 is a PROTAC BCL-XL Degrader
2020-06-18
XZ739 is a PROTAC BCL-XL Degrader. XZ739 is potent against various cancer cell lines. PROTAC is an emerging therapeutic modality. -
JCN037 is a potent, non-covalent, and brain-penetrant EGFR tyrosine kinase inhibitor. JCN037 has potent anti-cancer activity.
-
RA-9 is a potent and selective proteasome-associated DUBs inhibitor with favorable toxicity profile and anticancer activity.
-
HLI373 represents a potential drug-able lead for the development of therapeutically efficacious inhibitors of Hdm2. Hdm2 is an ubiquitin protein ligase.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
RA375, a RPN13 inhibitor, inhibits proteasome function in muscle. RA375 is highly active against cell lines of multiple myeloma and diverse solid cancers.
-
KCC-07 prevents binding of MBD2 to methylated DNA and activates BAI1 inducing anti-proliferative BAI1/p53/p21 signaling. Anticancer activity.
-
CAY10404 is a potent and highly selective COX-2 inhibitor. CAY10404 is a potent inhibitor of PKB/Akt and MAPK signalling pathways.
-
MPT0G211, an orally active and selective HDAC6 inhibitor, ameliorates tau phosphorylation, and cognitive deficits in an Alzheimer’s disease model.
-
RapaLink-1, a third-generation bivalent mTOR inhibitor, potently blocking cancer-derived, activating mutants of mTOR. It can cross the blood-brain barrier.
-
SJF620 is a Potent PROTAC BTK Degrader
2020-09-26
SJF620 is a potent PROTAC BTK degrader with improved pharmacokinetic properties. Contains a Lenalidomide analog for recruiting CRBN. -
BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC) and does not induce CDK6 and IKZF1/3 degradation with anti-cancer activity.
-
BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC) and does not induce IKZF1/3 degradation with anti-cancer activity.
-
KB02-SLF is a PROTAC-based nuclear FKBP12 degrader. KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase).
-
DT2216 is a potent and selective BCL-XL degrader based on PROTAC technology. DT2216 inhibits leukemia and has potent anti-cancer activity.
-
dTRIM24 will be a useful tool to further probe the function of TRIM24 by rapid chemical depletion in hematopoietic cancers and other biological contexts.
-
ZXH-3-26 is a Selective PROTAC BRD4 Degrader
2020-11-17
ZXH-3-26 is a Selective PROTAC BRD4 Degrader and allows pharmacologic targeting of BRD4 without significant inhibition or degradation of BRD2/3. -
BETd-260 is a Potent PROTAC BET Degrader
2020-11-18
BETd-260 is a highly potent, efficacious, and promising BET degrader. -
SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology by recruiting VHL E3 ubiquitin ligase. SIAIS178 has anticancer activity.
-
GNE-987, a potent chimeric BET degrader, exhibits picomolar cell BRD4 degradation activity. GNE-987 can be used in PROTAC-Antibody Conjugate (PAC).
-
BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with cereblon ligands to hijack E3 ligases for PTK2 degradation.
-
dFKBP-1 induces potent and dose-dependent degradation of FKBP12 in 293FT-WT cells. A facile and general new strategy to control target protein stability.
-
UNC6852 is a chemical degrader that targets polycomb repressive complex 2 (PRC2). Anti-proliferative in diffuse large B cell lymphoma cell lines.
-
VZ185 is a highly selective, potent, and rapid dual degrader with a slight preference for BRD9 over BRD7.
-
PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor. Antitumor activity.
-
MZP-54 is a Selective BRD3/4 PROTAC Degrader
2020-12-02
MZP-54 is a PROTAC that would link together specific VHL ligand and BET bromodomain ligand. MZP-54 induces degradation of BRD3/4. -
BMS-P5 is an Orally Active PAD4 Inhibitor
2020-12-12
BMS-P5 is an orally active PAD4 inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model -
ML132, a potent and selective caspase 1 inhibitor with a unique selectivity pattern, is responsible for the proteolytic activation of IL-1β and IL-18.
-
CHDI-390576, a potent and CNS penetrant class IIa HDAC inhibitor, show selectivity over class I HDACs, HDAC8 and the class IIb HDAC6 isoform.
-
BI-3802, a BCL6 degrader, inhibits the BCL6 BTB domain. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1.
-
JH-XI-10-02, a highly Potent CDK8 Degrader, modulates the CDK8 protein levels. A viable therapeutic strategy in cancer.
-
dCBP-1 is a potent and selective degrader of p300/CBP based on PROTAC. dCBP-1 is exceptionally potent at killing multiple myeloma cells.
-
PR-619 is a Broad-Range DUB Inhibitor
2021-02-20
PR-619, a broad-spectrum deubiquitinating enzyme (DUB) inhibitor, induces ER stress and ER-stress related apoptosis. -
NAZ2329 is an allosteric, noncompetitive and reversible inhibitor of R5 RPTP subfamily and PTPRZ/PTPRG with anti-cancer activity.
-
CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
BrBzGCp2 is a Glyoxalase 1 (GLO1) inhibitor for a variety of disorders. Possesses antitumor and neuroprotective activity.
-
Conglobatin inhibits proliferation and induces apoptosis by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
-
YUM70 inhibits GRP78. Induces endoplasmic reticulum stress-mediated apoptosis. Pancreatic cancer. Acts as a novel anticancer agent.
-
LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM.
-
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist. SB-332235 inhibits acute and chronic models of arthritis in the rabbit.
-
ML-00253764 is a brain penetrant nonpeptidic melanocortin receptor 4 (MC4R) antagonist with a Ki/IC50 of 0.16 µM/0.103 µM, respectively.
-
PROTAC MDM2 degrader MD-222 is highly potent and effective in inducing degradation of MDM2 and in activating wild-type p53 in cells.
-
Butaprost is a selective prostaglandin E receptor (EP2) agonist. Butaprost can effectively mitigate kidney fibrogenesis in various fibrosis models.
-
Lenalidomide, a CRBN ligand, is an orally active immunomodulator that effective treatment for myelodysplastic syndrome and multiple myeloma.
-
AUTAC4 is a mitochondria-targeting autophagy-targeting chimera, which can be used for the study of mitochondrial dysfunction.
-
ARV-110 is an orally active, specific androgen receptor (AR) PROTAC degrader. ARV-110 can be used for the research of prostate cancer.
-
Vorasidenib is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor.
-
BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC). BSJ-4-116 exhibits potent antiproliferative effects.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Lumiracoxib is a COX-2 inhibitor. Lumiracoxib acts as nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities.
-
SJ6986 is a selective and orally active GSPT1/GSPT2 degrader, displaying selectivity over classical IMiD neosubstrates, such as IKZF1/3
-
DP-C-4 is a CRBN-Based dual PROTAC for EGFR and PARP could provide an effective study for cancer diseases.
-
XY028-140 is a potent and selective PROTAC-based CDK4/6 degrader, which can inhibit RB-E2F signaling and reduce CDK4 and CDK6 protein levels.
-
NRX-2663 is a potent enhancer of the interaction between β-catenin SCFβ-TrCP, potentiates the ubiquitylation of mutant β-Catenin by β-TrCP.
-
SIM1 is a PROTAC Based BET Family Degrader
2021-08-11
SIM1 is a potent von Hippel-Lindau (VHL)-based trivalent PROTAC capable of degradation for all BET family members. -
Iberdomide (CC-220) is an orally active cereblon (CRBN) E3 ligase modulator (CELMoD) with antitumor and immunostimulatory activities。
-
Ruxolitinib is a potent and selective JAK1/2 inhibitor and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy.
-
GSK2606414 is an orally available PERK inhibitor and is a potent compound of cancer and neurological diseases.
-
Ganetespib (STA-9090) is a HSP90 Inhibitor
2021-10-14
Ganetespib is a unique Hsp90 inhibitor that exhibits potent and sustained antitumor effects in a broad range of malignancies. -
SB 258719 is a selective 5-HT7 receptor antagonist and can be used for the research of cancer and neurological disease.
-
MB710 is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1 μM.
-
IMD-0354 is a Selective IKKβ Inhibitor
2021-11-09
IMD-0354 is a selective IKKβ inhibitor and potently inhibits NF-κB activity. IMD0354 has antitumor activity. -
Trolox is an analogue of vitamin E with a powerful antioxidant effect. Trolox is also a powerful inhibitor of membrane damage.
-
AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC50 of 0.78 nM.
-
MS4322 is a first-in-class PRMT5 degrader and a valuable chemical tool for exploring the PRMT5 functions in vitro and in vivo.
-
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Zingerone is a natural orally active nontoxic methoxyphenol potent anti-inflammatory, antidiabetic, antioxidize, and anti-tumor properties.
-
MS170 is a PROTAC AKT Degrader
2022-02-27
MS170 is a CRBN-recruiting degrader, the AKT proteolysis targeting chimera (PROTAC) degrader. -
AUTAC2 is a FKBP12-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG and an SLF moiety.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Oprozomib (PR-047) is an orally active peptide epoxyketone proteasome inhibitor.
-
Epoxomicin is an epoxyketone-containing natural product and a selective and irreversible proteasome inhibitor. Cross the blood-brain barrier.
-
DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis.
-
PU-H54 is a potent purine-based (PU) Grp94-selective inhibitor. PU-H54 has the potential for the research of breast cancer.
-
Pelecopan is a potent, selective, and orally active complement factor D inhibitor, possessing the potential to study paroxysmal nocturnal hemoglobinuria (PNH).
-
MS159 is a frist-In-class nuclear receptor binding SET NSD2 PROTAC degrader for multiple myeloma research.
-
ARV-471 is an oral estrogen receptor PROTAC degrader for breast cancer. ARV-471 robustly degrades ER in ER-positive breast cancer cell lines.
-
AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6.
-
ARD-69 is a potent PROTAC androgen receptor degrader and induces degradation of AR protein in AR-positive prostate cancer cell lines.
-
GR-46611 is a 5-HT1D Receptor Agonist
2022-10-11
GR-46611 is a potent 5-HT1D receptor agonist and has the potential for the research of epilepsy and inhibits bladder activity. -
Golcadomide is a potent and orally active CRBN E3 ligase modulator with immunomodulating and antineoplastic activities.
-
Etrolizumab is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research
2022-11-05
Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody and has the potential for the research of inflammatory bowel disease. -
U7D-1 is a selective USP7 PROTAC degrader. U7D-1 induces apoptosis in Jeko-1 cells and shows anticancer activity.
-
Olutasidenib (FT-2102) is an orally active, brain penetrant inhibitor of mutant IDH1. Olutasidenib is used for AML or MDS Research.
-
A947 is a selective SMARCA2 (PROTAC). A947 also is a moderately selective SMARCA2 degrader. A947 can be used for the research of cancer.
-
SJ988497 is a cell permeable PROTAC JAK2 degrader that degrades JAK2 in vitro and in vivo, and shows anticancer activity against leukemia.
-
MMRi62, a Ferroptosis inducer targeting MDM2-MDM4. MMRi62 shows a P53-independent pro-apoptotic activity against PDAC cells.
-
TD1092 is a pan-IAP degrader, degrades cIAP1, cIAP2, and XIAP. TD1092 inhibits NF-κB pathway and epithelial-mesenchymal transition (EMT).
-
SIAIS100 is a Potent BCR-ABL PROTAC Degrader
2023-01-10
SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC50 value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML). -
YX-2-107 is a PROTAC that selectively degrades CDK6.
-
SZUH280, a potent and selective PROTAC HDAC8 degrader, ,shows antitumor activity in an A549 nude mouse model.
-
MS8815 is a selective EZH2 PROTAC degrader. MS8815 can be used for the research of triple-negative breast cancer (TNBC),
-
J-113397 is a potent and selective nonpeptidyl ORL1 receptor antagonist without any agonistic effects on other opioid receptors.
-
Ruxolitinib is an orally-active JAK1/2 inhibitor. Ruxolitinib has the potential for the research of myeloproliferative neoplasm (MPN).
-
dBRD9 is a PROTAC (proteolysis targeting chimera) and can be used as a selective valuable probe for degrading BRD9.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
Induced Disease Models Products
-
GMP Small Molecules
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-18739 | Phorbol 12-myristate 13-acetate |
Phorbol 12-myristate 13-acetate (PMA; TPA; Phorbol myristate acetate), a phorbol ester, is a dual SphK and protein kinase C (PKC) activator. Phorbol 12-myristate 13-acetate is a NF-κB activator. Phorbol 12-myristate 13-acetate induces differentiation in THP-1 cells (Validated by MedChemExpress).
|
|
860
|
| HY-16658B | Z-VAD-FMK |
Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis.
|
|
850
|
| HY-D0940 | H2DCFDA |
H2DCFDA (DCFH-DA) is a cell-permeable probe used to detect intracellular reactive oxygen species (ROS) (Ex/Em=488/525 nm).
|
|
838
|
| HY-B0215 | Acetylcysteine |
Acetylcysteine (N-Acetylcysteine) is a mucolytic agent that can cross the blood-brain barrier, which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies.
|
Reactive Oxygen Species (ROS)
Endogenous Metabolite
Apoptosis
Ferroptosis
Influenza Virus
Disulfidptosis
Neurological, Eye or Ear Disease
Digestive System Disease
Breast Cancer
Viral Infection
Digestive System Inflammation
SARS-CoV-2 Infection
Lung Fibrosis
|
757
|
| HY-10071 | Y-27632 |
Y-27632 is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade.
|
|
602
|
| HY-100218A | RSL3 |
RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
|
|
573
|
| HY-13453 | BAY 11-7082 |
BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
507
|
| HY-B0988 | Deferoxamine mesylate |
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
|
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
452
|
| HY-D1055 | MitoSOX Red |
MitoSOX Red is a live cell fluorescent probe that specifically targets mitochondria and is cell membrane permeable. MitoSOX Red enters mitochondria and is oxidized by superoxide but not by other ROS or RNS generating systems. The oxidized MitoSOX Red then binds to nucleic acids in mitochondria/nucleus, producing strong red fluorescence. MitoSOX Red can be used as a fluorescent indicator to specifically detect superoxide. In addition, superoxide dismutase (SOD) can prevent the oxidation of MitoSOX Red.
Excitation/emission wavelength: 510/580 nm. |
|
328
|
| HY-10227 | Bortezomib |
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
|
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Depression
Pain
Non-Small Cell Lung Cancer
Metastatic Breast Cancer
SARS-CoV-2 Infection
Obesity
|
278
|
| HY-18085 | Quercetin |
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Pain
Digestive System Inflammation
SARS-CoV-2 Infection
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
230
|
|
| HY-13982 | JSH-23 |
JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Glucose Metabolism
Obesity
|
162
|
| HY-40354 | Tofacitinib |
Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
|
|
103
|
| HY-L025 | Anti-Cancer Compound Library |
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.
MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
|
|
100
|
| HY-100487 | TAK-243 |
TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC50=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
96
|
| HY-B0166 | L-Ascorbic acid |
L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells.
|
Neurological, Eye or Ear Disease
Pancreatic Cancer
Digestive System Inflammation
Glucose Metabolism
SARS-CoV-2 Infection
Hypertension
|
91
|
| HY-L015 | PI3K/Akt/mTOR Compound Library |
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.
MCE owns a unique collection of 1,149 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.
|
|
90
|
| HY-L081 | Phosphatase Inhibitor Library |
Protein phosphorylation is a key post-translational modification underlying the regulation of many cellular processes. Phosphatases and kinases contribute to the regulation of protein phosphorylation homeostasis in the cell. This reversible regulation of protein phosphorylation is critical for the proper control of a wide range of cellular activities, including cell cycle, proliferation and differentiation, metabolism, cell-cell interactions, etc.
Protein phosphatases have evolved in separate families that are structurally and mechanistically distinct. Based on substrate specificity and functional diversity, protein phosphatases are classified into two superfamilies: Protein serine/threonine phosphatases and Protein tyrosine phosphatases. Ser/Thr phosphatases are metalloenzymes belonging to two major gene families termed PPP (phosphoprotein phosphatase) and PPM (metal-dependent protein phosphatases), whereas protein tyrosine phosphatases (PTPs) belong to distinct classes of enzymes that utilize a phospho-cysteine enzyme intermediate as a part of their catalytic action.
MCE supplies a unique collection of 185 phosphatase inhibitors that mainly targeting protein tyrosine phosphatases (PTPs) and serine/threonine-specific protein phosphatases. MCE Phosphatase Inhibitor Library is a useful tool for phosphatase drug discovery and related research.
|
|
87
|
| HY-L017 | Stem Cell Signaling Compound Library |
Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.
MCE owns a unique collection of 2,931 compounds that can be used for stem cell regulatory and signaling pathway research.
|
|
86
|
| HY-L020 | Wnt/Hedgehog/Notch Compound Library |
The developmental proteins Hedgehog, Notch and Wnt are key regulators of cell fate, proliferation, migration and differentiation in several tissues. Their related signaling pathways are frequently activated in tumors, and particularly in the rare subpopulation of cancer stem cells.
The Wnt signaling pathway is a conserved pathway in animals. Deregulated Wnt signaling has catastrophic consequences for the developing embryo and it is now well appreciated that defective Wnt signaling is a causative factor for a number of pleiotropic human pathologies, including cancer. Hedgehog signaling pathway is linked to tumorigenesis and is aberrantly activated in a variety of cancers. The Notch signaling pathway is a highly conserved cell signaling system present in most animals. It plays an important role in cell-cell communication, and further regulates embryonic development.
MCE designs a unique collection of 654 Wnt/Hedgehog/Notch signaling pathway-related small molecules. Wnt/Hedgehog/Notch Compound Library serves as a useful tool for stem cell research and anti-cancer drug screening.
|
|
86
|
| HY-L014 | NF-κB Signaling Compound Library |
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.
MCE owns a unique collection of 1,801 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.
|
|
85
|
| HY-L037 | Antioxidant Compound Library |
Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer.
MCE Antioxidant Compound Library contains 2,489 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.
|
|
85
|
| HY-L034 | Anti-Aging Compound Library |
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.
MCE Anti-Aging Compound Library contains 7,771 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.
|
|
84
|
| HY-L051 | Ferroptosis Compound Library |
Ferroptosis is a novel type of cell death program that is distinct from apoptosis, necroptosis and autophagy. It is dependent on iron and reactive oxygen species (ROS) and is characterized by lipid peroxidation. As a novel type of cell death, ferroptosis has distinct properties and recognizing functions involved in physical conditions or various diseases including cancers, neurodegenerative diseases, acute renal failure, etc.
MCE carefully collected a unique collection of 1,255 ferroptosis signaling pathway related compounds with ferroptosis-inducing or -inhibitory activity. MCE Ferroptosis Compound Library is a useful tool to study ferroptosis mechanism as well as related diseases.
|
|
84
|
| HY-L151 | PROTAC Library |
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy.
MCE supplies a unique collection of 544 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.
|
|
84
|
| HY-L038 | Differentiation Inducing Compound Library |
Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.
MCE Differentiation Inducing Compound Library contains a unique collection of 2,574 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.
|
|
83
|
| HY-L039 | Reprogramming Compound Library |
Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.
MCE Reprogramming Compound Library contains a unique collection of 3,231 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.
|
|
83
|
| HY-L045 | Oxygen Sensing Compound Library |
Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.
HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O2 concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.
MCE offers a unique collection of 4,317 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.
|
|
83
|
| HY-L074 | Anti-Breast Cancer Compound Library |
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).
Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.
MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.
|
|
83
|
| HY-L090 | Transcription Factor-Targeted Library |
Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential.
MCE offers a unique collection of 2,569 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.
|
|
83
|
| HY-L103 | Anti-Colorectal Cancer Compound Library |
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.
Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research.
MCE offers a unique collection of 2,653 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.
|
|
83
|
| HY-L124 | Anti-Prostate Cancer Compound Library |
Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.
MCE offers a unique collection of 3,655 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.
|
|
83
|
| HY-L166 | Ion Channel Compound Library |
Ion channel is a membrane-binding enzyme whose catalytic site is an ion conduction pore, which is opened and closed in response to specific environmental stimuli (voltage, ligand concentration, membrane tension, temperature, etc.). Ion channel provide pores for the passive diffusion of ions on the biofilm. Due to their high selectivity for ion, ion channel are generally classified as sodium (Na+ ), potassium (K+ ), calcium (Ca2+ ), chloride (Cl- ), and non-specific cation channel. Ion channel is an important contributor to cell signal transduction and homeostasis. In addition to electrical signal transduction, ion channel also have many functions: regulating vascular smooth muscle contraction, maintaining normal cell volume, regulating glandular secretion, protein kinase activation, etc. Therefore, dysfunction of ion channel can lead to many diseases, and its mechanism research is particularly important.
MCE designs a unique collection of 1,751 small molecules related to ion channel, mainly targeting Na+ channel, K+ channel, Ca2+ channel, GABA receptor, iGluR, etc. It is an essential tool for research of cardiovascular diseases, Nervous system diseases and other diseases.
|
|
83
|
| HY-L172 | Immunopotentiator Compound Library |
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines.
MCE designs a unique collection of 150 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.
|
|
83
|
| HY-L175 | Inflammasomes related Compound Library |
Inflammasomes are classic pattern recognition receptors for natural immune responses. Inflammasomes are polymeric protein complexes that regulate inflammatory responses and pyrolytic cell death, thereby exerting the host's defense against microorganisms. Inflammasomes sensors are associated with adapter proteins, activating inflammatory caspase-1, releasing inflammatory cytokines and inducing cell death, endowing the host with defense against pathogens. NLRP1, NLRP3, NLRC4, AIM2, and pyrin are considered typical inflammasomes because they convert cysteine asparaginase-1 into catalytically active capsaicin-1. In addition to infectious diseases, the importance of inflammasomes is also related to various clinical diseases, such as autoimmune diseases, neurodegeneration and metabolic disorders, and the development of cancer. Therefore, it is necessary to strictly regulate the activation and function of inflammasomes to avoid accidental host tissue damage while inducing pathogens to kill the inflammatory response.
MCE designs a unique collection of 178 inflammasomes related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L199 | Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library |
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.
MCE designs a unique collection of 5,024 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.
|
|
83
|
| HY-L201 | Cell Proliferation Compound Library |
Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.
MCE collects 3,628 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.
|
|
83
|
| HY-L237 | Pattern Recognition Receptors Library |
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions.
MCE has cataloged 338 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.
|
|
83
|
| HY-L249 | Lactylation Compound Library |
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis.
MCE has assembled a collection of 6,182 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.
|
|
83
|
| HY-L914 | Serine/Threonine Focused Covalent Fragment Library |
In the research of covalent inhibitors targeting serine and threonine, scientists have found that the nucleophilicity of these hydroxyl groups is significantly enhanced due to the influence of their surrounding environment. This results in higher activity during catalytic reactions. Aspirin, which targets the non-catalytic domain serine (Ser529 in human COX1) of cyclooxygenase, exerts its anti-inflammatory effect through covalent binding. β-lactam antibiotics, which targets the catalytic domain serine of penicillin-binding proteins, interferes with bacterial cell wall synthesis.
Through careful selection, we constructed a structural filter containing over 110 electrophilic groups. By analyzing the electrophilic fragments selected by the structural filter, we removed any molecules with trivial or undesirable structural features. Ultimately, we obtained 3,300 fragment molecules which can target serine and threonine residues and can be used for fragment-based covalent drug discovery.
|
|
83
|
| HY-L934 | CRBN Ligand Library |
CRBN, namely cereblon, is the substrate recognition subunit of the E3 ubiquitin ligase complex in the ubiquitin-proteasome system. A CRBN ligand library refers to a collection of numerous fragments that can specifically bind to the CRBN protein.
These ligands are mostly designed based on validated CRBN-binding warheads and modified through AI-driven molecular generation optimization systems. They not only include classic lenalidomide-derived structures but also cover novel non-lenalidomide scaffolds. After drug-likeness filtering, these ligands exhibit structural diversity and favorable druggable properties. They can be further optimized and modified to facilitate the development of novel molecular glue degraders, accelerate the discovery of molecular glues that induce interactions between CRBN and new substrate proteins, and enable the exploration of novel CRBN substrates for identifying previously unknown CRBN-binding proteins.
MCE compiles 122 fragments that can specifically bind to the CRBN protein, with molecular weights ranging from 200 to 500. Compounds developed based on the library ligands target multiple disease targets such as cancer and autoimmune diseases, further advancing the development of Molecular Glues and PROTACs therapeutic agents.
|
|
83
|
| HY-L942 | Allosteric Modulator Fragment Library |
Unlike highly conserved orthosteric sites, allosteric sites exhibit low conservation, high hydrophobicity, weak polarity, confined geometry, and dynamic cryptic properties. Rather than rigid keyhole-like cavities, they typically appear as flexible grooves, subunit interface clefts, or shallow depressions formed by protein conformational changes.
Based on the dynamic, hydrophobic, and elongated nature of allosteric pockets, MCE has carried out targeted fragment modification and screening under strict physicochemical criteria: MW 120–280 Da, HBD ≤ 2, HBA ≤ 3, PSA 30–80 Ų, rotatable bonds ≤ 2, cLogP 1–3.5. High 3D diversity was further ensured by PMI analysis, yielding fragments with excellent shape complementarity to allosteric pockets.
This library contains 1,800 structurally diverse, drug-like fragments, this library supports allosteric drug development and pocket optimization. It significantly improves screening hit rates and enables efficient, precise early-stage R&D of allosteric drugs.
|
|
83
|
| HY-32735 | Triptolide |
Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Depression
Pain
Digestive System Inflammation
Obesity
|
76
|
| HY-18234A | Leupeptin hemisulfate |
Leupeptin hemisulfate is a broad-spectrum protease inhibitor. By inhibiting the activation of the PTEN/PI3K/Akt/NF-κB/ERK1/2/p38 signaling pathway, Leupeptin hemisulfate significantly reduces LPS-induced NO and ROS production, mitochondrial membrane potential hyperpolarization, phagocytic activity, pro-inflammatory cytokine release, and M1 polarization in mouse peritoneal macrophages, and reverses autophagic flux impairment. It also decreases Concanavalin A (HY-P2149)-induced proliferation index of mouse splenic lymphocytes and the Th1/IL-10 and Th2/IL-10 cytokine ratios, thereby modulating innate and adaptive immune responses. Leupeptin hemisulfate inhibits blood coagulation and tumorigenesis in mouse skin. Leupeptin hemisulfate can be used in research on chronic inflammatory diseases and skin tumorigenesis.
Source: Streptomyces roseus MB-26-AI |
Ser/Thr Protease
Cathepsin
Autophagy
SARS-CoV
Atg8/LC3
NO Synthase
COX
p62
Arginase
PTEN
NF-κB
PI3K
Akt
p38 MAPK
ERK
Reactive Oxygen Species (ROS)
|
68
|
| HY-B0764 | Bucladesine sodium |
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation.
|
|
52
|
| HY-114118B | Semaglutide acetate |
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
|
|
50
|
| HY-114118A | Semaglutide TFA |
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
|
|
50
|
| HY-114118 | Semaglutide |
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
|
|
50
|
| HY-P0151 | SN50 |
SN50 is a cell permeable inhibitor of NF-κB translocation.
|
|
45
|
| HY-15027 | 5-Aminosalicylic Acid |
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
|
|
43
|
| HY-N0191 | Andrographolide |
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Parasitic Infection
Depression
Pain
Digestive System Inflammation
SARS-CoV-2 Infection
Obesity
|
35
|
|
| HY-13821 | Epoxomicin |
Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible proteasome inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity.
Source: actinomycete strain NumberQ996-17 |
|
28
|
| HY-13207A | ONX-0914 TFA |
ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 TFA is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 TFA reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1.
|
|
26
|
| HY-13207 | ONX-0914 |
ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1.
|
|
26
|
| HY-N0560 | Oroxylin A |
Inflammation or Immune System Disease
Breast Cancer
Prostate Cancer
Ovarian Cancer
Viral Infection
Depression
Pain
|
20
|
|
| HY-N0143A | Phlorizin dihydrate |
Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities.
|
|
18
|
| HY-143218 | TPE-MI |
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasites Plasmodium falciparum .
|
|
18
|
| HY-N0629 | Maslinic acid |
Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Bacterial Infection
Depression
Pain
Digestive System Inflammation
Glucose Metabolism
Obesity
|
17
|
| HY-B0167A | Sodium Salicylate |
Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a S6K inhibitor.Sodium Salicylate is a NF-κB inhibitor that decreases inflammatory gene expression and improves repair in aged muscle.
|
Environmental Pollutants
Apoptosis
NF-κB
Endogenous Metabolite
Autophagy
Ribosomal S6 Kinase (RSK)
COX
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Glucose Metabolism
SARS-CoV-2 Infection
Obesity
Rheumatoid Arthritis
|
16
|
| HY-N0441 | Neferine |
Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Glucose Metabolism
Obesity
|
16
|
| HY-N0274 | Caffeic acid phenethyl ester |
Caffeic acid phenethyl ester is a NF-κB inhibitor.
Source: Propolis |
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
16
|
| HY-P1860A | TNF-α (31-45), human TFA |
|
13
|
|
| HY-P1860 | TNF-α (31-45), human |
|
13
|
|
| HY-15594A | Phen-DC3 Trifluoromethanesulfonate |
Phen-DC3 Trifluoromethanesulfonate is a bisquinolinium G-quadruplex (G4) ligand. Phen-DC3 Trifluoromethanesulfonate selectively binds to and stabilizes the hybrid quadruplex-duplex hybrid (QDH) derived from the PIM1 promoter. Phen-DC3 Trifluoromethanesulfonate also binds to the c-myc promoter Pu24T G4 via extensive π-stacking, and induces polymerase stalling at α-synuclein DNA and RNA G4 sequences. Phen-DC3 Trifluoromethanesulfonate downregulates LPS (HY-D1056)-induced TNFRSF21, RIPK3 and p-MLKL in VECs, and ameliorates CLP-induced pulmonary vascular leakage in septic rats. Phen-DC3 Trifluoromethanesulfonate can be used in studies related to neurodegenerative diseases and sepsis-associated vascular injury.
|
|
12
|
| HY-N0510A | Aristolochic acid A sodium |
Aristolochic acid A (Aristolochic acid I) sodium is the main component of plant extract Aristolochic acids, which are found in various herbal plants of genus Aristolochia and Asarum. Aristolochic acid A sodium significantly reduces both activator protein 1 (AP-1) and NF-κB activities. Aristolochic acid A sodium reduces BLCAP gene expression in human cell lines.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
11
|
| HY-153169 | 6PPD-Q |
6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation.
6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders.
|
|
11
|
| HY-K1056 | G418 Selective Antibiotic, Sterile |
MCE G418 Selective Antibiotic, Sterile (50 mg/mL) is an aminoglycoside antibiotic produced by Micromonospora rhodorangea. It acts by binding to the 80S subunit of the bacterial ribosome, thus inhibiting protein synthesis in both prokaryotic and eukaryotic cells. |
|
9
|
| HY-P1934 | Cyclo(Phe-Pro) |
Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) is a quorum-sensing molecule of Vibrio vulnificus that specifically interacts with RIG-I, inhibiting RIG-I polyubiquitination, suppressing IRF-3 activation, and reducing type I interferon production. Cyclo(Phe-Pro) enhances susceptibility to HCV and influenza virus and also alleviates plant aluminum toxicity stress. The mechanism of Cyclo(Phe-Pro) involves the regulation of host immune signaling pathways, bacterial virulence gene expression, and plant antioxidant systems, making it a promising candidate for research in viral infections, bacterial virulence regulation, and agricultural stress resistance.
|
|
8
|
| HY-P80839 | Phospho-NF-KB p65 (Ser536) Antibody |
Phospho-NF-KB p65 (Ser536) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-NF-KB p65 (Ser536).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
8
|
| HY-P80245 | NF-KB p65 Antibody (YA267) |
NF-KB p65 Antibody (YA267) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NF-KB p65.
Host: Rabbit; Reactivity: Human, Mouse |
|
7
|
| HY-119970 | Helenalin |
|
6
|
|
| HY-113308A | Taurolithocholic acid sodium salt |
Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
Source: animals |
|
6
|
| HY-P1290 | PKA Inhibitor Fragment (6-22) amide |
PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of PKA, with Ki values of 1.7 nM and 1.6 nM against human and bovine PKA catalytic subunits, respectively. The IC50 of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing.
|
|
5
|
| HY-111790 | M3258 |
M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC50=3.6 nM) and cellular (IC50=3.4 nM) potency against the LMP7 subunit. M3258 shows strong antitumor efficacy in multiple myeloma xenograft models. M3258 leads to a significant and prolonged suppression of tumor LMP7 activity and ubiquitinated protein turnover and the induction of apoptosis in multiple myeloma cells.
|
|
5
|
| HY-114419 | Zetomipzomib |
Zetomipzomib (KZR-616), a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases.
|
|
4
|
| HY-114419A | Zetomipzomib maleate |
Zetomipzomib (KZR-616) maleate, a first-in-class immunoproteasome inhibitor, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP2/mLMP2) subunits of the immunoproteasome. Zetomipzomib maleate has the potential for the research of multiple autoimmune diseases.
|
|
4
|
| HY-B1899A | Taurodeoxycholic acid sodium hydrate |
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway.
|
|
4
|
| HY-N1501 | Beta-asarone |
Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of α-synuclein, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases.
|
Inflammation or Immune System Disease
Cardiovascular Disease
Alzheimer's Disease
Parkinson's Disease
|
4
|
| HY-W015883A | Fumaric acid disodium |
Fumaric acid disodium is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid disodium exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid disodium can be used in the study of pregnancy-induced hypertension.
|
|
4
|
| HY-N0743 | Senkyunolide A |
Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and α-synuclein phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis.
|
|
4
|
| HY-12113 | Oprozomib |
Oprozomib (PR-047) is an orally bioavailable and selective peptide epoxyketone proteasome inhibitor with IC50s of 36 and 82 nM for proteasome (β5) and immunoproteasome (LMP7), respectively. Oprozomib (ONX 0912) induces apoptosis in MM cells.
|
|
4
|
| HY-P81238 | Phospho-NF-κB p65 (Ser536) Antibody |
Phospho-NF-κB p65 (Ser536) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-NF-κB p65 (Ser536).
Host: Rabbit; Reactivity: Human, Mouse, Rat, Monkey |
|
4
|
| HY-P3414 | Proteasome-activating peptide 1 |
Proteasome-activating peptide 1 is a peptide, which increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis.
|
|
3
|
| HY-P10350 | PapRIV |
PapRIV is an agonist of BV-2 microglial cells, capable of activating microglial cells through an NF-κB-dependent pathway. PapRIV induces the expression of pro-inflammatory cytokines such as IL-6 and TNFα and increases the production of reactive oxygen species (ROS). PapRIV can cross the blood-brain barrier.
|
|
3
|
| HY-P1832 | PTD-p65-P1 Peptide |
PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis.
|
|
3
|
| HY-P9958A | Denosumab (anti-TNFSF11) |
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies.
Species: Human |
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Non-Small Cell Lung Cancer
HER-2 Positive Breast Cancer
Metastatic Breast Cancer
|
3
|
| HY-P1832A | PTD-p65-P1 Peptide TFA |
PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis.
|
|
3
|
| HY-N0694 | Schisantherin A |
Schisantherin A is a dibenzocyclooctadiene lignan. Schisantherin A inhibits p65-NF-κB translocation into the nucleus by IκBα degradation.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
3
|
| HY-P9958 | Denosumab |
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies.
Species: Human |
Metabolic or Endocrine Disease
Non-Small Cell Lung Cancer
HER-2 Positive Breast Cancer
Metastatic Breast Cancer
|
3
|
| HY-K1050 | Gentamicin, Sterile |
MCE Gentamicin, Sterile (10 mg/mL) is a filtered and sterilized antibiotic solution that can be used directly in cell culture. Gentamicin acts by binding to the 30S subunit of the bacterial ribosome leading to inhibition of protein synthesis and death in susceptible bacteria, mainly for gram-negative and gram-positive bacteria. |
|
3
|
| HY-N1987 | Cucurbitacin IIb |
Cucurbitacin IIb is an active component isolated from Hemsleya amabilis, induces apoptosis with anti-inflammatory activity. Cucurbitacin IIb inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB (p65), blocks nuclear translocation of NF-κB (p65) and decreases mRNA levels of IκBα and TNF-α.
|
|
2
|
| HY-N0277 | Aconine |
Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
2
|
| HY-W016412 | Coenzyme Q0 |
Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling.
|
Apoptosis
Autophagy
EGFR
Akt
mTOR
Caspase
Bcl-2 Family
Reactive Oxygen Species (ROS)
PARP
COX
NO Synthase
TNF Receptor
Interleukin Related
MMP
NF-κB
|
2
|
| HY-Y0669 | Pipecolic acid |
Pipecolic acid is an orally bioavailable, blood-brain barrier-permeable metabolite of lysine with antioxidant, inhibitor, and inducer activity. Pipecolic acid modulates the YAP-GPX4 signaling pathway, reduces retinal vascular tube formation, and mitigates ferroptosis. Pipecolic acid potentiates voltage-sensitive Ca2+ channel currents and induces neuronal apoptosis. Pipecolic acid can be used for the research of diabetic retinopathy.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
2
|
| HY-W001171 | 3-Hydroxyanthranilic acid |
3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases.
|
Cancer
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
Cardiovascular Disease
|
2
|
| HY-P80470 | Phospho-NF-κB p65 (Ser529) Antibody (YA170) |
Phospho-NF-κB p65 (Ser529) Antibody (YA170) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-NF-κB p65 (Ser529).
Host: Rabbit; Reactivity: Human |
|
2
|
| HY-P80847 | Phospho-PKA R2/PKR2 (Ser99) Antibody |
Phospho-PKA R2/PKR2 (Ser99) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-PKA R2/PKR2 (Ser99).
Host: Rabbit; Reactivity: Human, Mouse, Rat, Pig |
|
2
|
| HY-113308AS | Taurolithocholic acid-d4 sodium |
Taurolithocholic acid-d4 (sodium) is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
|
|
1
|
| HY-10201S4 | Sorafenib-d3 tosylate |
Sorafenib-d3 (Donafenib) tosylate is the deuterated-labeled Sorafenib tosylate (HY-10201A). Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
|
Isotope-Labeled Compounds
Raf
VEGFR
FLT3
Autophagy
Apoptosis
STAT
Akt
MMP
Cadherin
p38 MAPK
ERK
MEK
PI3K
PARP
Bcl-2 Family
Neurological, Eye or Ear Disease
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Digestive System Inflammation
Non-Small Cell Lung Cancer
Metastatic Breast Cancer
SARS-CoV-2 Infection
Lung Fibrosis
|
1
|
| HY-D0914A | Fast green FCF free acid |
Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function.
|
|
1
|
| HY-P992354 | FPA154 |
FPA154 is a human monoclonal antibody against TNFRSF18/GITR/CD357. FPA154 activates NF-κB via the GITR pathway. FPA154 can be used in solid tumor research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
1
|
| HY-113308S1 | Taurolithocholic acid-d4 |
Taurolithocholic acid-d4 is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
|
|
1
|
| HY-N1074 | Warangalone |
Warangalone is an anti-malarial compound which can inhibit the growth of both strains of parasite 3D7 (chloroquine sensitive) and K1 (chloroquine resistant) with IC50s of 4.8 μg/mL and 3.7 μg/mL, respectively. Warangalone can also inhibit cyclic AMP-dependent protein kinase catalytic subunit (cAK) with an IC50 of 3.5 μM.
|
|
1
|
| HY-10201S2 | Sorafenib-13C,d3 |
Sorafenib-13C,d3 (Bay 43-9006-13C,d3) is the 13C, deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
|
Isotope-Labeled Compounds
Raf
VEGFR
FLT3
Autophagy
Apoptosis
STAT
Akt
MMP
Cadherin
p38 MAPK
ERK
MEK
PI3K
PARP
Bcl-2 Family
Gastric Cancer
Liver Cancer
Ovarian Cancer
Digestive System Inflammation
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Metastatic Breast Cancer
Metastatic Colorectal Cancer
Metastatic Prostate Cancer
Multiple Myeloma
Metastatic Pancreatic Cancer
SARS-CoV-2 Infection
Alzheimer's Disease
Parkinson's Disease
Obesity
Lung Fibrosis
|
1
|
| HY-P99524 | Vatelizumab |
Vatelizumab (GBR500) is a monoclonal antibody that targets the α2 subunit (CD49b) of very late antigen 2 (VLA-2). Vatelizumab can be used for research on multiple sclerosis.
Species: Human |
|
1
|
| HY-W338584 | Hydroxycitric acid tripotassium |
Tripotassium hydroxycitrate is an orally active, multi-target, multi-bioactive organic acid. Tripotassium hydroxycitrate activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Tripotassium hydroxycitrate activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Tripotassium hydroxycitrate activates both the AMPK and mTORC1/S6K pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation.
|
Keap1-Nrf2
Ferroptosis
Apoptosis
mTOR
NF-κB
ATP Citrate Lyase
AMPK
Ribosomal S6 Kinase (RSK)
DNA/RNA Synthesis
|
1
|
| HY-B1864A | Kasugamycin hydrochloride |
Kasugamycin (Ksg) hydrochloride is an aminoglycoside antibiotic (antibiotic) that binds to the bacterial 30S ribosomal subunit and inhibits canonical translation initiation. Kasugamycin hydrochloride binds to the P-site and E-site codon regions in the mRNA channel and interferes with mRNA-tRNA codon-anticodon interactions, thereby destabilizing initiator tRNA binding. Kasugamycin hydrochloride possesses anti-infective activity. Kasugamycin hydrochloride is used in research on bacterial translation and Pseudomonas infection.
Source: Streptomyces kasugaensis |
|
1
|
| HY-N1380S1 | Guaiacol-d3 |
|
1
|
|
| HY-P1004A | Luciferase, firefly |
Luciferase, firefly is the light-emitting enzyme responsible for the bioluminescence of fireflies and click beetles. Luciferase, firefly catalytic substrate is D-luciferin (HY-12591B).
|
|
1
|
| HY-W097899 | Vanillylamine |
Vanillylamine is an immediate precursor for capsaicinoids. Vanillylamine is a derivative of Vanillin (HY-N0098) is synthesized through a transaminase reaction in the phenylpropanoid pathway of capsaicinoid synthesis. Vanillylamine significantly alleviates myelosuppression caused by abdominal and pelvic tumor chemotherapy.
|
|
1
|
| HY-W105750 | 6-Hydroxyhexanoic acid |
6-Hydroxyhexanoic acid (6-HHA) is a bacterial effector molecule with metabolic and immunomodulatory activities. 6-Hydroxyhexanoic acid activates the JAK1-STAT1 signaling pathway, promotes phenotypic conversion of M2 macrophages to M1 macrophages, and exerts anti-tumor effects by regulating macrophage polarization. 6-Hydroxyhexanoic acid inhibits lipolysis in adipocytes mediated by Gαi family GPCR, and reduces high-fat diet-induced weight gain and obesity. 6-Hydroxyhexanoic acid can be used in studies related to pancreatic ductal adenocarcinoma, obesity, and insulin resistance.
|
|
1
|
| HY-N0481 | Roburic acid |
Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a Ki of 7.066 μM against human TNF, an IC50 of 9 μM against human COX-2, and an IC50 of 5 μM against ovine COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6 in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases.
|
COX
TNF Receptor
NO Synthase
Interleukin Related
NF-κB
Apoptosis
p38 MAPK
JNK
ERK
Keap1-Nrf2
RANKL/RANK
|
1
|
| HY-B0167S | Salicylic acid-d6 |
Salicylic acid-d6 is a deuterium labeled Salicylic acid (HY-B0167). Salicylic acid inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation.
|
|
1
|
| HY-P99376 | Narsoplimab |
|
1
|
|
| HY-D0914 | Fast Green FCF |
Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function.
|
|
1
|
| HY-10201S | Sorafenib-d3 |
Sorafenib-d3 (Donafenib) is the deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
|
Isotope-Labeled Compounds
Raf
VEGFR
FLT3
Autophagy
Apoptosis
STAT
Akt
MMP
Cadherin
p38 MAPK
ERK
MEK
PI3K
PARP
Bcl-2 Family
Gastric Cancer
Liver Cancer
Ovarian Cancer
Digestive System Inflammation
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Metastatic Breast Cancer
Metastatic Colorectal Cancer
Metastatic Prostate Cancer
Multiple Myeloma
Metastatic Pancreatic Cancer
SARS-CoV-2 Infection
Alzheimer's Disease
Parkinson's Disease
Obesity
Lung Fibrosis
|
1
|
| HY-W042416 | N,N-Dimethylacetamide |
N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the NF-κB signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
1
|
| HY-W011474 | Geranylgeraniol |
Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model.
Source: Halobacterium cutirubrum |
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
1
|
| HY-P76759 | Calcineurin A/PPP3CA Protein, Human (sf9, His) |
The calcineurin A/PPP3CA protein is a calcium-dependent, calmodulin-stimulated phosphatase. PPP3CA inhibits MAP3K14/NIK signaling and SLC9A1 activity. PPP3CA is involved in processes such as kidney development, salivary enzyme secretion, hippocampal homosynaptic depotentiation, keratinocyte survival, bone formation, and T cell proliferation. Calcineurin A/PPP3CA Protein, Human (sf9, His) is the recombinant human-derived Calcineurin A/PPP3CA protein, expressed by Sf9 insect cells , with N-His labeled tag.
Species: Human; Source: Sf9 insect cells |
|
1
|
| HY-P86339 | DNA PKcs Antibody (YA6031) |
DNA PKcs Antibody (YA6031) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DNA PKcs.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
1
|
| HY-K1051 | Hygromycin B, Sterile |
MCE Hygromycin B, Sterile (50 mg/mL) is a filtered and sterilized antibiotic solution that can be used directly in cell culture.Hygromycin B is an aminoglycosidic antibiotic purified from Streptomyces hygroscopicus. It acts by binding to the 70S subunit of the bacterial ribosome and inhibiting protein synthesis, leading to the death of bacteria, fungi and mammalian cells. |
|
1
|
| HY-13821R | Epoxomicin (Standard) |
Epoxomicin (Standard) is the analytical standard of Epoxomicin (HY-13821). This product is intended for research and analytical applications. Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible proteasome inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity.
|
|
/
|
| HY-10201S1 | Sorafenib-d4 |
Sorafenib-d4 (Bay 43-9006-d4) is the deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
|
Isotope-Labeled Compounds
Raf
VEGFR
FLT3
Autophagy
Apoptosis
STAT
Akt
MMP
Cadherin
p38 MAPK
ERK
MEK
PI3K
PARP
Bcl-2 Family
Gastric Cancer
Liver Cancer
Ovarian Cancer
Digestive System Inflammation
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Metastatic Breast Cancer
Metastatic Colorectal Cancer
Metastatic Prostate Cancer
Multiple Myeloma
Metastatic Pancreatic Cancer
SARS-CoV-2 Infection
Alzheimer's Disease
Parkinson's Disease
Obesity
Lung Fibrosis
|
/
|
| HY-136610S | Chlorpyrifos-oxon-d10 |
Chlorpyrifos-oxon-d10 is the deuterium labeled Chlorpyrifos-oxon. Chlorpyrifos-oxon, an active metabolite of Chlorpyrifos, is a potent phosphorylating agent that potently inhibits AChE. Chlorpyrifos-oxon can induce cross-linking between subunits of tubulin and disrupt microtubule function.
|
|
/
|
| HY-W013150S | Alpidem-d14 |
Alpidem-d14 is the deuterium labeled Alpidem (HY-W013150). Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
|
|
/
|
| HY-178898 | 7-Oxogedunin |
7-Oxogedunin (Compound 7DG; Compound 16) is a small molecule that protects macrophages from cell pyroptosis induced by anthrax lethal toxin (LT). Its target is protein kinase R (PKR). 7-Oxogedunin can widely inhibit the assembly of various inflammasomes (NLRP1 and NLRP3) and the activation of caspase-1 by inhibiting the kinase-independent function of PKR. 7-Oxogedunin has growth inhibitory activity on European corn borer larvae. 7-Oxogedunin can be used for LT toxicity inhibition and pest control research.
|
|
/
|
| HY-P992345 | DS002 |
DS002 is a human monoclonal antibody targeting NGF/bNGF, with an IC50 of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks NGF-TrkA binding, interrupts pain signal transduction, inhibits TrkA-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy.
Species: Human |
|
/
|
| HY-P991475 | MG-1131 |
MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-12292G | IM-12 (GMP) |
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca2+ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABLT315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia.
|
|
/
|
| HY-142920 | LMP7-IN-1 |
LMP7-IN-1, a Boronic acid derivative, is a potent and selective immunoproteasome subunit LMP7 (β5i) inhibitor with an IC50 of 1.83 nM (WO2021143923A1; compound 20).
|
|
/
|
| HY-P11660 | β-catenin-IN-10 |
β-catenin-IN-10 is a β-catenin:TCF4 interaction inhibitor with an IC50 of 5.44 μM. β-catenin-IN-10 inhibits the Wnt and AR signaling pathways with IC50 values of 0.105 μM and 1.02 μM, respectively. β-catenin-IN-10 suppresses the proliferation of castration-resistant prostate cancer cells. β-catenin-IN-10 is applicable to research related to prostate cancer.
|
|
/
|
| HY-10227G | Bortezomib (GMP) |
Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
|
|
/
|
| HY-149696 | IR-Crizotinib |
IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research.
|
|
/
|
| HY-B1864AR | Kasugamycin hydrochloride (Standard) |
Kasugamycin hydrochloride (Standard) (Ksg hydrochloride (Standard)) is the analytical standard of Kasugamycin hydrochloride (HY-B1864A). This product is intended for research and analytical applications. Kasugamycin (Ksg) hydrochloride is an aminoglycoside antibiotic (antibiotic) that binds to the bacterial 30S ribosomal subunit and inhibits canonical translation initiation. Kasugamycin hydrochloride binds to the P-site and E-site codon regions in the mRNA channel and interferes with mRNA-tRNA codon-anticodon interactions, thereby destabilizing initiator tRNA binding. Kasugamycin hydrochloride possesses anti-infective activity. Kasugamycin hydrochloride is used in research on bacterial translation and Pseudomonas infection.
|
|
/
|
| HY-N1380S4 | Guaiacol-d4-1 |
|
/
|
|
| HY-N10332 | Leptosphaerodione |
Leptosphaerodione, isolated from Remotididymella sp. Fungus, is a potent ubiquitin-proteasome system (UPS) inhibitor. Leptosphaerodione exhibits cytotoxicity in HeLa cells with IC50 value of 3.2 μM. Anti-tumor agent.
Source: Remotididymella sp. |
|
/
|
| HY-P991528 | PE0116 |
PE0116 is a fully human CD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model.
Species: Human |
|
/
|
| HY-P992369 | HMBD-002 |
HMBD-002 is an Fc-independent, non-depleting IgG4 subclass antibody that targets VISTA and VSIG3. It is widely used in research related to various solid tumors, including colon cancer, triple-negative breast cancer, and non-small cell lung cancer. HMBD-002 blocks the interactions of VISTA with VSIG3 and LRIG1, relieves immunosuppression without depleting VISTA-positive cells, activates the cytotoxic program of CD8+ T cells, and drives the type I interferon signaling pathway. HMBD-002 reprograms tumor-associated macrophages to the M1 phenotype, reduces tumor infiltration of inhibitory myeloid cells, thereby significantly inhibiting tumor growth and improving survival. HMBD-002 is well tolerated in rodent and non-human primate animal models.
Species: Human |
|
/
|
| HY-P3162 | (Ala13)-Apelin-13 |
(Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway.
|
|
/
|
| HY-N1380S | Guaiacol-d7 |
|
/
|
|
| HY-P10081 | CTP-NBD |
CTP-NBD is a cell permeable specific NFκB peptide inhibitor. CTP-NBD could be used in colitis study
|
|
/
|
| HY-P1847 | IKKγ NBD Inhibitory Peptide |
IKKγ NBD Inhibitory Peptide is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits.
|
|
/
|
| HY-Y0332L | Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340 |
Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340 (Potassium phosphate monobasic, meets analytical specification of Ph. Eur., NF, E340) is a potassium salt. Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340 activates NF-κB. Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340 upregulates the expression of dental/osteogenic markers (OCN, DSP/DSPP, OSX, RUNX2, ALP) and enhances the mineralization capacity of human periodontal ligament stem cells. Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340 promotes the proliferation of human periodontal ligament stem cells in logarithmic growth phase. Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340 promotes the growth of somatic embryos of Dendrobium Sonia, increases leaf number, leaf length and fresh weight of tissue-cultured seedlings. Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340 is applicable to periodontal disease-related research.
|
|
/
|
| HY-P11595 | TBZ-1 |
TBZ-1 is a fluorescent probe that monitors the activity of immunoproteasome (Proteasome) (iCP) in cells. TBZ-1 undergoes fluorescence activation after being selectively cleaved by β5i, which is used for intracellular activity monitoring. TBZ-1 is applicable to cancer-related research.
|
|
/
|
| HY-N11739 | Helenalin isobutyrate |
|
/
|
|
| HY-P4202A | Suc-Ala-Glu-Pro-Phe-pNA TFA |
|
/
|
|
| HY-N0390G | L-Glutamine (GMP) |
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
|
/
|
| HY-P992462 | SHR-1806 |
SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector T cells, suppresses regulatory T cells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer.
Species: Human |
|
/
|
| HY-W777002 | Famotidine-13C3 |
Famotidine-13C3 (MK-208-13C3) is the 13C3-labeled Famotidine (HY-B0377). Famotidine (MK-208) is an orally active and highly selective histamine H2 receptor antagonist. It inhibits gastric acid secretion by blocking the Gs signaling pathway, and regulates intracellular cAMP and ERK pathways. Famotidine inhibits TLR3-mediated inflammatory pathways, and reduces the expression of various inflammatory mediators and interferon-related genes. Famotidine scavenges DPPH and nitric oxide free radicals, alleviates oxidative stress damage in gastric tissue, inhibits proMMP-9, improves vascular endothelial permeability, and restores the normal physiological functions of neutrophils and eosinophils. Famotidine crosses intestinal epithelial cells via facilitated diffusion and passive diffusion, blocks paracellular cation transport, and increases intestinal transepithelial electrical resistance. Famotidine reduces serum levels of transaminases and alkaline phosphatase, exerts analgesic effects and gastric protective effects simultaneously. Famotidine can be used in studies related to COVID-19, liver injury and acute gastric ulcer.
|
|
/
|
| HY-P11914 | Peptide CYP9 |
Peptide CYP9 is a head-to-tail cyclic peptide derived from Antimicrobial peptide YD (HY-P11913). Peptide CYP9 inhibits the activation of the TGF-β/Smad signaling pathway, including the phosphorylation of Smad2/3. Peptide CYP9 inhibits the activation of the MAPK signaling pathway, including the phosphorylation of ERK and p38. Peptide CYP9 inhibits epithelial-mesenchymal transition. Peptide CYP9 inhibits extracellular matrix synthesis. Peptide CYP9 can be used for the research of pulmonary fibrosis.
|
|
/
|
| HY-DY1024 | TPE-MI (solution) |
TPE-MI (Tetraphenylethene maleimide) (solution) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
Solvent and concentration: DMSO: 10 mM |
|
/
|
| HY-P10854 | TAT-N15 |
TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke.
|
|
/
|
| HY-P10469 | NBD-2 |
NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the NF-κB signaling pathway. NBD-2 specifically inhibits the typical NF-κB signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to NF-κB signaling pathway, including autoimmune diseases, cancer, etc.
|
|
/
|
| HY-P992321 | BAY-356 |
BAY-356, a potent TWEAK receptor agonist, is an aglycosylated anti-TWEAK receptor antibody. BAY-356 triggers TWEAKR hyperactivation, activates NFκB and STAT1 pathways, and undergoes TWEAKR-dependent internalization. BAY-356 can be used for the research of colorectal cancer, bladder cancer, non-small cell lung cancer and pancreatic cancer[1][2].
Species: Human |
|
/
|
| HY-P992399 | LBL-019 |
LBL-019 is a humanized IgG1 monoclonal antibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001).
Species: Human |
|
/
|
| HY-W707517 | Famotidine-d4 |
Famotidine-d4 (MK-208-d4) is the deuterated-labeled Famotidine (HY-B0377). Famotidine (MK-208) is an orally active and highly selective histamine H2 receptor antagonist. It inhibits gastric acid secretion by blocking the Gs signaling pathway, and regulates intracellular cAMP and ERK pathways. Famotidine inhibits TLR3-mediated inflammatory pathways, and reduces the expression of various inflammatory mediators and interferon-related genes. Famotidine scavenges DPPH and nitric oxide free radicals, alleviates oxidative stress damage in gastric tissue, inhibits proMMP-9, improves vascular endothelial permeability, and restores the normal physiological functions of neutrophils and eosinophils. Famotidine crosses intestinal epithelial cells via facilitated diffusion and passive diffusion, blocks paracellular cation transport, and increases intestinal transepithelial electrical resistance. Famotidine reduces serum levels of transaminases and alkaline phosphatase, exerts analgesic effects and gastric protective effects simultaneously. Famotidine can be used in studies related to COVID-19, liver injury and acute gastric ulcer.
|
|
/
|
| HY-N1380S2 | Guaiacol-13C6 |
|
/
|
|
| HY-P3110 | Ac-DNLD-AMC |
Ac-WLA-AMC is a fluorogenic substrate of caspase-3. Ac-WLA-AMC is cleaved to release the fluorescent moiety 7-amino-4-methylcoumarin (AMC), which can be used to quantify the β5c subunit activity.
|
|
/
|
| HY-N13917 | Argyrin B |
Argyrin B, a natural product cyclic peptide, is a reversible, non-competitive immunoproteasome inhibitor. Argyrin B shows selective inhibition of the β5i and β1i sites of the immunoproteasome over the β5c and β1c sites of the constitutive proteasome with nearly 20-fold selective inhibition of β1i over the homologous β1c. Argyrin B has antibacterial effects.
|
|
/
|
| HY-114265 | Guanosine 3',5'-bisdiphosphate |
Guanosine 3',5'-bisdiphosphate (ppGpp) is a guanosine derivative that inhibits guanylate kinase. Guanosine 3',5'-bisdiphosphate binds to the β' subunit of plastid-encoded bacterial-type RNA polymerase, inhibits the catalytic activity of guanylate kinase, and regulates chloroplast translation and GTP biosynthesis. Guanosine 3',5'-bisdiphosphate acts as a plant chloroplast signaling molecule and a global bacterial regulator, and plays a role in microbial persistence. Guanosine 3',5'-bisdiphosphate is applicable to biosynthesis-related research.
|
|
/
|
| HY-D1493 | FIM-1 |
|
/
|
|
| HY-P991265 | OSE-703 |
OSE-703 is a humanized monoclonal antibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases.
Species: Human |
|
/
|
| HY-W724290 | Tetrabutylammonium-d36 bromide |
Tetrabutylammonium-d36 bromide (AP 6G-d36 bromide) is the deuterium labeled Tetrabutylammonium bromide (HY-D0172). Tetrabutylammonium bromide is an organic ammonium compound, which is often used in catalytic reactions and separation and purification processes. It has a significant catalytic effect in some organic synthesis reactions, and can be used as a surfactant, stabilizer and antibacterial agent, etc. In addition, in some laboratory studies, this compound has also been used as an ion exchanger, solvent extractant, etc.
|
|
/
|
| HY-163967 | Clindamycin 2,4-diphosphate |
Clindamycin 2,4-diphosphate is a related impurity of Clindamycin phosphate (HY-B1064), a prodrug of Clindamycin (HY-B1455). Clindamycin phosphate inhibits protein synthesis by targeting the bacterial ribosomal 50S subunit.
|
|
/
|
| HY-113308AS2 | Taurolithocholic acid-d4-1 sodium |
Taurolithocholic acid-d4-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
|
|
/
|
| HY-14664DS | (3S,5R)-Fluvastatin-d6 |
(3S,5R)-Fluvastatin-d6 is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive?HMG-CoA reductase?inhibitor with an IC50?of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
|
|
/
|
| HY-183683 | DQ-9 |
DQ-9 is a selective immunoproteasome β5i inhibitor (IC50=0.0019 μM). DQ-9 generates additional inhibitory substances via iron-mediated intracellular activation, and induces oxidative stress, carbon-centered free radicals and macromolecular damage through its artemisinin domain. DQ-9 induces apoptosis in leukemia and multiple myeloma cells. DQ-9 exhibits selective cytotoxicity against leukemia and multiple myeloma cells by elevating the labile iron pool. DQ-9 can be used in the research of hematological malignancies (leukemia, multiple myeloma, mantle cell lymphoma, acute myeloid leukemia).
|
|
/
|
| HY-113308S | Taurolithocholic acid-d5 |
Taurolithocholic acid-d5 is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
|
|
/
|
| HY-128854S | Dimethyl biphenyl-4,4'-dicarboxylate-d8 |
Dimethyl biphenyl-4,4'-dicarboxylate-d8 is the d8-labeled Dimethyl biphenyl-4,4'-dicarboxylate (HY-128854). Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) is a hepatoprotective agent. Dimethyl biphenyl-4,4'-dicarboxylate stimulates the Jak/Stat signaling pathway and induces the expression of IFN-α-stimulated genes, particularly 6-16 and ISG12. Dimethyl biphenyl-4,4'-dicarboxylate inhibits the replication of pregenomic RNA and HBeAg. Polymer micelles loaded with Dimethyl biphenyl-4,4'-dicarboxylate can serve as carriers for the compound. Dimethyl biphenyl-4,4'-dicarboxylate can be used as an auxiliary improving agent for chronic hepatitis. Dimethyl biphenyl-4,4'-dicarboxylate is applicable to research related to chronic hepatitis B.
|
|
/
|
| HY-P992463 | SHR-2010 |
|
/
|
|
| HY-W157144 | Diethyl disulfide |
Diethyl disulfide, an organosulfur compound, is a chemical reactant and an industrial catalyst with excellent catalytic activity.
Source: Marine Bacteria of the Roseobacter Clade |
|
/
|
| HY-N1380S3 | Guaiacol-d4 |
|
/
|
|
| HY-P10002A | EWFW-ACC TFA |
EWFW-ACC TFA is a specific immunoproteasome substrate that can be used to study immunoproteasome function.
|
|
/
|
| HY-D1687 | Flubi-2 |
Flubi-2 is a fluorescein-biotin based pH-ratio dye (Ex=480 nm, Em= 520-560 nm) with a pK value of 6.7. Flubi-2 is a hydrolysis product of Flubida-2 (non-fluorescent, membrane permeable). Flubi-2 can be used for pH determination of organelles of the secretory pathway (such as golgi apparatus and endoplasmic reticulum) in living cells.
|
|
/
|
| HY-P991432 | VTX-0811 |
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma.
Species: Human |
|
/
|
| HY-P992053 | Anti-CD11a Antibody (MHM24) |
Anti-CD11a Antibody (MHM24) is a monoclonal antibody targeting murine CD11a. Anti-CD11a Antibody (MHM24) binds to high-affinity (open) and low-affinity (closed) conformations of the αL subunit of LFA-1, and functionally blocks LFA-1-mediated interactions. Anti-CD11a Antibody (MHM24) blocks ICAM-1 binding to LFA-1-expressing cells. Anti-CD11a Antibody (MHM24) inhibits adhesion of high-affinity LFA-1-expressing cells to keratinocytes. Anti-CD11a Antibody (MHM24) inhibits PHA-induced lymphocyte proliferation. Anti-CD11a Antibody (MHM24) can be used for the research of inflammatory and autoimmune diseases. Recommend Isotype Controls: mouse IgG1 kappa, Isotype Control (HY-P99977).
Species: Human |
|
/
|
| HY-W754654 | Epothilone B-d3 (synthetic) |
Epothilone B-d3 (synthetic) is the deuterium labeled Epothilone B (HY-17029). Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.
|
|
/
|
| HY-126389A | Chitin, from shrimp shells (powder) |
Chitin, from shrimp shells (powder) is a long-chain polymer of N-acetylglucosamine with β-(1-4) linkages. Chitin, from shrimp shells (powder) is found in the exoskeleton of crabs. Chitin, from shrimp shells (powder) inhibits the activation of NF-κB p65, alters the translocation of NF-κB p65 to the nucleus, and interacts with the cell wall of Candida species. Chitin, from shrimp shells (powder) exerts antifungal and anti-inflammatory effects. Chitin, from shrimp shells (powder) can be used in the research of gastric ulcer and candidiasis.
|
|
/
|
| HY-N0191S | Andrographolide-d |
Andrographolide-d (Andrographis-d) is the deuterium labeled Andrographolide (HY-N0191). Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
|
|
/
|
| HY-126389C | Chitin, from crab carapace |
Chitin, from crab carapace is a long-chain polymer of N-acetylglucosamine with β-(1-4) linkages. Chitin, from crab carapace is found in the exoskeleton of crabs. Chitin, from crab carapace inhibits the activation of NF-κB p65, alters the translocation of NF-κB p65 to the nucleus, and interacts with the cell wall of Candida species. Chitin, from crab carapace exerts antifungal and anti-inflammatory effects. Chitin, from crab carapace can be used in the research of gastric ulcer and candidiasis.
Source: Holotrichia parallela |
|
/
|
| HY-P11502 | COG112 |
COG112 is an antennapedia-linked apoE-mimetic peptide. COG112 attenuates induction of NO production, inhibits CXC chemokines KC and MIP-2. COG112 reduces nuclear translocation of NF-κB. COG112 inhibits phosphorylation of IκB-α and prevents the degradation of IκB-α. COG112 inhibits the inflammatory response to Citrobacter rodentium .
|
|
/
|
| HY-P991994 | REGN9533 |
REGN9533 is a human-derived monoclonal antibody against FXII/FXIIa with high affinity for FXII, FXIIa and β-FXIIa. REGN9533 selectively inhibits the intrinsic coagulation pathway and FXIIa-driven plasma kallikrein activity. REGN9533 is applicable to FXIIa-related diseases such as thrombosis and hereditary angioedema.
Species: Human |
|
/
|
| HY-P991993 | AB054 |
AB054 is a humanized monoclonal antibody targeting factor XII (FXII). AB054 inhibits FXII activation and FXIIa activity through specific binding to the catalytic domain of FXII, and exerts antithrombotic effects in a concentration-dependent manner. AB054 can be used in studies related to thrombosis.
Species: Human |
|
/
|
| HY-B0377S | Famotidine-13C,d3 |
Famotidine-13C,d3 (MK-208-13C,d3) is the deuterated, 13C-labeled Famotidine (HY-B0377). Famotidine (MK-208) is an orally active and highly selective histamine H2 receptor antagonist. It inhibits gastric acid secretion by blocking the Gs signaling pathway, and regulates intracellular cAMP and ERK pathways. Famotidine inhibits TLR3-mediated inflammatory pathways, and reduces the expression of various inflammatory mediators and interferon-related genes. Famotidine scavenges DPPH and nitric oxide free radicals, alleviates oxidative stress damage in gastric tissue, inhibits proMMP-9, improves vascular endothelial permeability, and restores the normal physiological functions of neutrophils and eosinophils. Famotidine crosses intestinal epithelial cells via facilitated diffusion and passive diffusion, blocks paracellular cation transport, and increases intestinal transepithelial electrical resistance. Famotidine reduces serum levels of transaminases and alkaline phosphatase, exerts analgesic effects and gastric protective effects simultaneously. Famotidine can be used in studies related to COVID-19, liver injury and acute gastric ulcer.
|
|
/
|
| HY-P6177 | SGP8 |
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH).
|
|
/
|
| HY-P11331 | Az-NC-002 |
Az-NC-002 is a Proteasome trypsin-like site (β2) and immunoproteasome β2i-specific active probe. Az-NC-002 has weak off-target effects with no significant inhibition for Cathepsin D (HY-P2750), but this inhibition reacts outside of the active site or influence on a small fraction of the enzyme.
|
|
/
|
| HY-182325 | DB-310 |
DB-310 is a selective immunoproteasome LMP2 inhibitor with an IC50 value of 80.62 nM. DB-310 inhibits the production of IL-1α in microglia. DB-310 improves cognitive function in the Tg2576 transgenic mouse model of Alzheimer's disease. DB-310 can be used for research related to Alzheimer's disease.
|
|
/
|
| HY-162754 | LMP7/LMP2-IN-1 |
LMP7/LMP2-IN-1 (Compound 19) is the orally active inhibitor for immunoproteasome subunits LMP7 and LMP2 with IC50 of 257 and 10 nM. LMP7/LMP2-IN-1 reduces the generation of antibody, downregulates the cells in spleen germinal center B and in plasma in NP-OVA-immunized mice, and can be used in research about autoimmune diseases.
|
|
/
|
| HY-179394 | Immunoproteasome-IN-2 |
Immunoproteasome-IN-2 is selective immunoproteasome inhibitor with IC50 = 232.3 nM for LMP7, IC50 = 9384.9 nM for β5. Immunoproteasome-IN-2 exhibits ancillary inhibitory activity against LMP2 and MECL-1 subunits. Immunoproteasome-IN-2 demonstrates anti-inflammatory efficacy in a mouse model of arthritis and shows a favorable safety profile in toxicological studies with reduced hepatotoxicity and hematotoxicity. Immunoproteasome-IN-2 has LMP7/β5 selectivity directly correlated with lower systemic toxicity. Immunoproteasome-IN-2 can be employed for research in arthritis.
|
|
/
|
| HY-W010179R | 2-Methoxynaphthalene (Standard) |
2-Methoxynaphthalene (Standard) is the analytical standard of 2-Methoxynaphthalene. This product is intended for research and analytical applications. 2-Methoxynaphthalene can be used to investigate the catalytic benefits of delamination, as well as to study alkali metal-mediated manganization (AMMMn) reactions.
|
|
/
|
| HY-D0205AS2 | Carbocisteine-d3 |
Carbocisteine-d3 (Carbocysteine-d3) is deuterium labeled Carbocisteine. Carbocisteine is an orally active mucolytic agent. Carbocisteine attenuates the phosphorylation of NF-κB p65 and ERK1/2. Carbocisteine modulates Nrf2/HO-1 and NFκB interplay. Carbocisteine inhibits Apoptosis. Carbocisteine is used in chronic obstructive pulmonary disease (COPD) research.
|
|
/
|
| HY-10082S1 | Triapine-d3 |
Triapine-d3 (3-AP-d3) is deuterium labeled Triapine. Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.
|
|
/
|
| HY-12848G | SAG (GMP) |
|
/
|
|
| HY-W031536R | 2-Imidazolidone, 96% (Standard) |
2-Imidazolidone, 96% (Standard) is the analytical standard of 2-Imidazolidone, 96%. This product is intended for research and analytical applications. 2-Imidazolidone, 96% is a chelating agent that forms complexes with metal ions, enabling its use in catalytic processes.
|
|
/
|
| HY-D2297 | AIE-GA |
|
/
|
|
| HY-101085G | SKL2001 (GMP) |
|
/
|
|
| HY-B0377S1 | Famotidine-13C |
Famotidine-13C (MK-208-13C) is the 13C-labeled Famotidine (HY-B0377). Famotidine (MK-208) is an orally active and highly selective histamine H2 receptor antagonist. It inhibits gastric acid secretion by blocking the Gs signaling pathway, and regulates intracellular cAMP and ERK pathways. Famotidine inhibits TLR3-mediated inflammatory pathways, and reduces the expression of various inflammatory mediators and interferon-related genes. Famotidine scavenges DPPH and nitric oxide free radicals, alleviates oxidative stress damage in gastric tissue, inhibits proMMP-9, improves vascular endothelial permeability, and restores the normal physiological functions of neutrophils and eosinophils. Famotidine crosses intestinal epithelial cells via facilitated diffusion and passive diffusion, blocks paracellular cation transport, and increases intestinal transepithelial electrical resistance. Famotidine reduces serum levels of transaminases and alkaline phosphatase, exerts analgesic effects and gastric protective effects simultaneously. Famotidine can be used in studies related to COVID-19, liver injury and acute gastric ulcer.
|
|
/
|
| HY-P10463 | ssK36 |
ssK36 is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2), and ssK36 is designed for the SETD2 protein, a specific PKMT. ssK36 is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency.
|
|
/
|
| HY-D0205AS1 | Carbocisteine-13C3-1 |
Carbocisteine-13C3-1 (Carbocysteine-13C3-1) is 13C labeled Carbocisteine. Carbocisteine is an orally active mucolytic agent. Carbocisteine attenuates the phosphorylation of NF-κB p65 and ERK1/2. Carbocisteine modulates Nrf2/HO-1 and NFκB interplay. Carbocisteine inhibits Apoptosis. Carbocisteine is used in chronic obstructive pulmonary disease (COPD) research.
|
|
/
|
| HY-W010179S1 | 2-Methoxynaphthalene-d2 |
2-Methoxynaphthalene-d2 is the deuterium labeled 2-Methoxynaphthalene (HY-W101130). 2-Methoxynaphthalene can be used to investigate the catalytic benefits of delamination, as well as to study alkali metal-mediated manganization (AMMMn) reactions.
|
|
/
|
| HY-D2227 | IR-58 |
IR-58, a mitochondria-targeting near-infrared (NIR) fluorophore, is an autophagy enhancer. IR-58 kills tumour cells and induces apoptosis via inducing excessive autophagy, which is mediated through the reactive oxygen species (ROS)-Akt-mTOR pathway.
|
|
/
|
| HY-Y0626S | Acetohydrazide-d3 |
Acetohydrazide-d3 (Ethanehydrazonic acid-d3) is deuterium labeled Acetohydrazide. Acethydrazide is an organic building that undergo catalytic hydrogenation to produce N′-methyl acethydrazide (MAH).
|
|
/
|
| HY-W127668 | Triethylcholine iodide |
Triethylcholine iodide is a choline acetyltransferase inhibitor and a regulator of the acetylcholine synthesis pathway. Triethylcholine iodide inhibits acetylcholine synthesis in brain tissues and blocks neuromuscular and autonomic ganglionic transmission. Triethylcholine iodide exerts weak curare-like effects at extremely high concentrations. Triethylcholine iodide elevates the pentylenetetrazol seizure threshold, alters electroencephalogram patterns in Felis catus, but does not affect the maximal electroshock seizure threshold in Oryctolagus cuniculus. Triethylcholine iodide can be used in seizure-related research.
|
|
/
|
| HY-W010451R | 1,2,4-Trihydroxybenzene (Standard) |
1,2,4-Trihydroxybenzene (Hydroxyhydroquinone) (Standard) is the analytical standard of 1,2,4-Trihydroxybenzene (HY-W010451). This product is intended for research and analytical applications. 1,2,4-Trihydroxybenzene (Hydroxyhydroquinone) is an ER stress inducer that targets proteins such as PKR-like ER kinase PERK to induce cytotoxicity. 1,2,4-Trihydroxybenzene selectively activates eIF2α phosphorylation, activates the PERK-eIF2α signaling pathway and induces stress granule formation. 1,2,4-Trihydroxybenzene subsequently exacerbates oxidative stress and causes DNA double-strand breaks, destroying organelles such as mitochondria and ER, and inducing cell death. 1,2,4-Trihydroxybenzene also has the potential to exhibit anti-tumor effect, increase blood pressure, and relieve spasm.
|
|
/
|
| HY-113308AS1 | Taurolithocholic Acid-d5 sodium salt |
Taurolithocholic Acid-d5 (sodium) is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic Acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic Acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic Acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic Acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic Acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic Acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
|
|
/
|
| HY-14855S | Tedizolid-13C,d3 |
Tedizolid-13C,d3 is the 13C- and deuterium labeled Tedizolid. Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
|
|
/
|
| HY-ER019 | Benzyltributylammonium chloride |
Benzyltributylammonium chloride is an organic salt compound, usually used in catalytic reactions and surfactants. It can play a catalytic role in some organic synthesis reactions, and can be used as a cleaning agent, lubricant and emulsifier. In addition, the compound is widely used in certain industrial fields, such as in the plastic, rubber and textile manufacturing processes.
|
|
/
|
| HY-P10463A | ssK36 TFA |
ssK36 TFA is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2) , and ssK36 TFA is designed for the SETD2 protein, a specific PKMT. ssK36 TFA is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 TFA can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 TFA can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency.
|
|
/
|
| HY-78131BS | (R)-(-)-Ibuprofen-d3 |
|
/
|
|
| HY-114295 | Geranyl diphosphate |
Geranyl diphosphate is a key intermediate in the isoprenoid biosynthesis pathway (IBP). HY-114295 plays key roles in cellular metabolism and is responsible for the production of both sterol and non-sterol isoprenoids.
|
|
/
|
| HY-144452 | Immunoproteasome inhibitor 1 |
Immunoproteasome inhibitor 1 is a potent, reversible, time-independent immunoproteasome and proteasome inhibitor (Kis of 1.18, 0.27, 1.91 μM in β5c, β1i, β5i submits, respectively). Immunoproteasome inhibitor 1 can be used for the research of certain neoplastic diseases.
|
|
/
|
| HY-W010179 | 2-Methoxynaphthalene |
2-Methoxynaphthalene can be used to investigate the catalytic benefits of delamination, as well as to study alkali metal-mediated manganization (AMMMn) reactions.
|
|
/
|
| HY-113066S2 | Guanosine 5'-diphosphate-d13 dilithium |
Guanosine 5'-diphosphate-d13 (GDP-d13) dilithium is deuterium labeled Guanosine 5'-diphosphate (HY-113066). Guanosine 5'-diphosphate (GDP) is a nucleoside diphosphate that activates adenosine 5'-triphosphate-sensitive K+ channel. Guanosine 5'-diphosphate is a potential iron mobilizer, which prevents the hepcidin-ferroportin interaction and modulates the interleukin-6 (IL-6)/stat-3 pathway. Guanosine 5'-diphosphate can be used in the research of inflammation, such as anemia of inflammation (AI).
|
|
/
|
| HY-P991720 | Tepilukimig |
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research.
Species: Human |
|
/
|
| HY-B0185G | Lidocaine (GMP) |
Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
|
|
/
|
| HY-113308AR | Taurolithocholic acid sodium salt (Standard) |
Taurolithocholic acid (sodium salt) (Standard) is the analytical standard of Taurolithocholic acid (sodium salt). This product is intended for research and analytical applications. Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
|
|
/
|
| HY-113066S | Guanosine 5'-diphosphate-15N5 dilithium |
Guanosine 5'-diphosphate-15N5 (GDP-15N5) dilithium is 15N labeled Guanosine 5'-diphosphate (HY-113066). Guanosine 5'-diphosphate (GDP) is a nucleoside diphosphate that activates adenosine 5'-triphosphate-sensitive K+ channel. Guanosine 5'-diphosphate is a potential iron mobilizer, which prevents the hepcidin-ferroportin interaction and modulates the interleukin-6 (IL-6)/stat-3 pathway. Guanosine 5'-diphosphate can be used in the research of inflammation, such as anemia of inflammation (AI).
|
|
/
|
| HY-P990057 | Picankibart |
Picankibart is a human-derived IgG1κ antibody targeting IL23A. Picankibart specifically binds to the IL23 p19 subunit and exerts an anti-inflammatory effect by blocking the IL23-mediated signaling pathway.
Species: Human |
|
/
|
| HY-P99417 | Abrezekimab |
|
/
|
|
| HY-113066S1 | Guanosine 5'-diphosphate-13C10 dilithium |
Guanosine 5'-diphosphate-13C10 (GDP-13C10) dilithium is 13C-labeled Guanosine 5'-diphosphate (HY-113066). Guanosine 5'-diphosphate (GDP) is a nucleoside diphosphate that activates adenosine 5'-triphosphate-sensitive K+ channel. Guanosine 5'-diphosphate is a potential iron mobilizer, which prevents the hepcidin-ferroportin interaction and modulates the interleukin-6 (IL-6)/stat-3 pathway. Guanosine 5'-diphosphate can be used in the research of inflammation, such as anemia of inflammation (AI).
|
|
/
|
| HY-W031536 | 2-Imidazolidone, 96% |
2-Imidazolidone, 96% is a chelating agent that forms complexes with metal ions, enabling its use in catalytic processes.
|
|
/
|
| HY-P11112 | PTD-DBM |
PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing.
|
|
/
|
| HY-P5269 | Palmitoyl tetrapeptide-10 |
Palmitoyl tetrapeptide-10 is a bioactive peptide. Palmitoyl tetrapeptide-10 works synergistically with other active ingredients to increase the expression of corneodesmosin (a marker of keratinocyte adhesion) and filaggrin (a marker of keratinocyte terminal differentiation), thereby reducing skin permeability and improving skin barrier function. Palmitoyl tetrapeptide-10 can be used in the research of sensitive skin syndrome and skin pigmentation.
|
|
/
|
| HY-D2188 | IMP-2373 |
IMP-2373 is a low-toxicity activity-based probe targeting covalent pan-deubiquitinase (DUB), which modulates and monitors DUB activity via covalent binding to the catalytic cysteine and active site of DUB. IMP-2373 enables real-time tracking of dynamic intracellular DUB activity in physiologically relevant living cell systems, and quantitative analysis of activity changes induced by pharmacological inhibition or MYC dysregulation. IMP-2373 can be used for research on related diseases such as B-cell lymphoma.
|
|
/
|
| HY-P99485 | Brazikumab |
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease.
Species: Human |
|
/
|
| HY-P99946 | Erlizumab |
Erlizumab (rhuMAb) is a monoclonal antibody against the Integrin b2/ITGB2/CD18 subunit of the Mac-1 receptor. Erlizumab can reduce reperfusion injury in myocardial infarction.
Species: Human |
|
/
|
| HY-181653 | PROTAC SKP2 Degrader-1 |
PROTAC SKP2 Degrader-1 is a PROTAC degrader targeting SKP2, with a Kd value of 6.28 μM. PROTAC SKP2 Degrader-1 induces targeted degradation of SKP2 via the ubiquitin-proteasome system. PROTAC SKP2 Degrader-1 stabilizes the expression of SOCS1 and regulates the expression of immunoproteasomes through the JAK/STAT pathway, thereby inhibiting tumor cell proliferation. PROTAC SKP2 Degrader-1 is applicable for cancer-related research.
|
|
/
|
| HY-D2361 | Adenosine 2'-PEG-Biotin |
Adenosine 2'-PEG-Biotin is a biochemical reagent derived from adenosine. Adenosine 2'-PEG-Biotin regulates cell signaling pathways by mimicking the effects of endogenous adenosine and binding to its receptors. Adenosine 2'-PEG-Biotin can be used in the research of bioprobes, biosensors and diagnostic reagents.
|
|
/
|
| HY-P99298 | Lampalizumab |
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.
Species: Human |
|
/
|
| HY-P10002 | EWFW-ACC |
EWFW-ACC is the tetrapeptide substrate for the immunoproteasome and has selectivity for the LMP7 subunits.
|
|
/
|
| HY-P10030 | DPLG3 |
DPLG3 is a specific chymotryptic-like β5i subunits inhibitor, with an IC50 of 4.5 nM. DPLG3 inhibits mouse i-20S with IC50 of 9.4 nM. DPLG3 downregulates the protein levels of NF-κB p50 and p65. DPLG3 can be used for immune disease research.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
/
|
| HY-P2208 | Z-IETD-AFC |
Z-IETD-AFC, a specific fluorescence substrate, can be used to determine the caspase-8 catalytic activity.
|
|
/
|
| HY-D2871 | DAyne |
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation.
|
|
/
|
| HY-126389B | Chitin, from shrimp shells (chitinase substrate) |
Chitin, from shrimp shells (chitinase substrate) serves as a substrate for chitinase. Chitin, from shrimp shells (chitinase substrate) is a long-chain polymer of N-acetylglucosamine with β-(1-4) linkages. Chitin, from shrimp shells (chitinase substrate) is found in the exoskeleton of crabs. Chitin, from shrimp shells (chitinase substrate) inhibits the activation of NF-κB p65, alters the translocation of NF-κB p65 to the nucleus, and interacts with the cell wall of Candida species. Chitin, from shrimp shells (chitinase substrate) exerts antifungal and anti-inflammatory effects. Chitin, from shrimp shells (chitinase substrate) can be used in the research of gastric ulcer and candidiasis.
|
|
/
|
| HY-P10602 | PKA Regulatory Subunit II Substrate |
PKA Regulatory Subunit II Substrate (RII phosphopeptide) is a tool peptide derived from the regulatory subunit Type II (RII) of cyclic AMP-dependent protein kinase (PKA). PKA Regulatory Subunit II Substrate is commonly used to mimic the phosphorylation of protein kinases and as a specific substrate for protein phosphatases to assess the activities of these enzymes.
|
|
/
|
| HY-P4279 | Ovalbumin (154-159) |
Ovalbumin (154-159) is a protein fragment consisting of residues 154-159 of chicken ovalbumin. Ovalbumin (154-159) is also a poorly conserved sequence (Thr-Asn-Gly-Ile-Ile-Arg) in the α-subunit of the Torpedo acetylcholine receptor, located within the α150-164 epitope region, and exhibits significant angiotensin-converting enzyme (ACE) inhibitory activity.
|
|
/
|
| HY-W011398 | Linoleate sodium |
Linoleate sodium is an orally active IL8 regulator via the JNK and NF-κB pathway. Linoleate sodium can change the composition of fatty acids and the production of metabolites in cells. Linoleate sodium has anti-inflammatory, immune-regulating, and tumor cell growth-affecting activities.
|
|
/
|
| HY-P991022 | Ruxoprubart |
Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy.
Species: Human |
|
/
|
| HY-162965 | Immunoproteasome activator 1 |
Immunoproteasome activator 1 (compound A) is a selective immunoproteasome activator that increases the presentation of individual MHC-I–bound peptides by over 100-fold. Immunoproteasome activator 1 binds to the proteasome structural subunit PSMA1 and promotes the association of the proteasome activator PA28α/β (PSME1/PSME2) with immunoproteasomes.
|
|
/
|
| HY-119663 | Averantin |
Averantin is the minor metabolite of the fungus Cercospora arachidicola. Averantin is an aflatoxin B1 precursor that can be used in the biosynthetic pathway.
Source: Fungi Aspergillus unguis 158SC-067 and A. flocculosus 01NT-1.1.5 |
|
/
|
| HY-P990952 | Zaltenibart |
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria.
Species: Human |
|
/
|
| HY-14774S | (Rac)-Monepantel-d5 |
(Rac)-Monepantel-d5 is deuterium labeled Monepantel. Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.
|
|
/
|
| HY-W009439 | Glucosamine 6-sulfate |
Glucosamine 6-sulfate (GlcN6P) is an organic cofactor that splits phosphodiester bonds. Glucosamine 6-sulfate plays a variety of catalytic roles in glmS ribozymes.
|
|
/
|
| HY-14774S1 | (Rac)-Monepantel sulfone-d5 |
(Rac)-Monepantel sulfone-d5 is deuterium labeled Monepantel. Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.
|
|
/
|
| HY-N3011 | Iridin |
Iridin is an orally active natural isoflavone. Iridin inhibits the PI3K/AKT and PKM2 signaling pathways, and downregulates the JAK/STAT and NF-κB pathways. Iridin induces Fas-mediated extrinsic apoptosis, G2/M cell cycle arrest, and inhibits cell proliferation. Iridin reduces inflammation, inhibits ROS production, suppresses glycolysis, and also exhibits antioxidant and antidiabetic activities. Iridin can be used in research related to gastric cancer and acute lung injury.
|
|
/
|
| HY-P11307 | Biotin-epoxomicin |
Biotin-epoxomicin is a Proteasome subunit binder. Biotin-epoxomicin serves as an affinity reagent for identifying proteasomal catalytic subunits, and facilitates affinity purification of active proteasomal subunits for LC-MS identification. Biotin-epoxomicin can be used to study solid tumors derived from B16 melanoma.
|
|
/
|
| HY-W008137 | 5-Bromo-2-fluoropyrimidine |
5-Bromo-2-fluoropyrimidine is a polyhalogenated pyrimidine and chemoselective amination substrate.5-Bromo-2-fluoropyrimidine undergoes chemoselective amination at the C-2 position (C-F bond) with no amination at the C-5 position (C-Br bond) in the presence of a Cu(II)/PTABS catalytic system.
|
|
/
|
| HY-114491 | Rineterkib |
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
|
|
/
|
| HY-119037 | UK-101 |
UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey. UK-101 induces cell apoptosis and can be used for the study of prostate cancer.
|
|
/
|
| HY-N0191R | Andrographolide (Standard) |
Andrographolide (Standard) is the analytical standard of Andrographolide. This product is intended for research and analytical applications. Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
|
|
/
|
| HY-P3162A | (Ala13)-Apelin-13 TFA |
(Ala13)-Apelin-13 TFA is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 TFA inhibits gastric motility through vagal cholinergic pathway.
|
|
/
|
| HY-148732 | LU-005i |
LU-005i is a potent inhibitor of β5i subunit of immunoproteasomes (IC50 = 6.6 nM), selective over β5c subunit (IC50 = 287 nM).
|
|
/
|
| HY-W010451 | 1,2,4-Trihydroxybenzene |
1,2,4-Trihydroxybenzene (Hydroxyhydroquinone) is an ER stress inducer that targets proteins such as PKR-like ER kinase PERK to induce cytotoxicity. 1,2,4-Trihydroxybenzene selectively activates eIF2α phosphorylation, activates the PERK-eIF2α signaling pathway and induces stress granule formation. 1,2,4-Trihydroxybenzene subsequently exacerbates oxidative stress and causes DNA double-strand breaks, destroying organelles such as mitochondria and ER, and inducing cell death. 1,2,4-Trihydroxybenzene also has the potential to exhibit anti-tumor effect, increase blood pressure, and relieve spasm.
Source: Phanerochaete chrysosporium |
Cancer
Digestive System Disease
Digestive System Inflammation
Cardiovascular Disease
Parkinson's Disease
|
/
|
| HY-N9497 | Galactinol |
Galactinol is a disaccharide carbohydrate serving as a galactosyl donor, which belongs to the raffinose family oligosaccharide pathway and acts as an important osmoprotectant. Galactinol not only induces disease resistance in plants against fungal and bacterial pathogens, but also significantly enhances plant tolerance to abiotic stresses such as drought, high salinity, low temperature and oxidative damage. In addition, Galactinol has the ability to scavenge hydroxyl radicals, can act as a signaling component for root colonization-induced systemic resistance, and is positively correlated with seed longevity in various crops, making it a potential biomarker for evaluating seed vigor. Therefore, Galactinol can be used in the research of various plant diseases including fungal leaf spot, bacterial angular leaf spot, gray mold and soft rot.
|
|
/
|
| HY-15001G | Stemregenin 1 (GMP) |
Stemregenin 1 (SR1) (GMP) is a GMP-grade Stemregenin 1 (HY-15001). GMP-grade small molecules can be used as adjuvants in cell therapy. Stemregenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with an IC50 of 127 nM. Stemregenin 1 (GMP) can competitively bind to AhR and inhibit its nuclear translocation, inhibiting osteoclastogenesis and promoting hematopoietic progenitor cell expansion by blocking the AhR-c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway. Stemregenin 1 (GMP) can be used for the study of osteoporosis, in vitro expansion of hematopoietic stem cells, and the study of the mechanism of bone metabolic diseases.
|
|
/
|
| HY-N9474 | Mevalonic acid 5-pyrophosphate tetralithium |
Mevalonic acid 5-pyrophosphate (5-Diphosphomevalonic acid) tetralithium is an endogenous metabolite of the mevalonate pathway.
|
|
/
|
| HY-112803 | GNE-371 |
GNE-371 is a potent and selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and transcription-initiation-factor TFIID subunit 1-like, with an IC50 of 10 nM for TAF1(2).
|
|
/
|
| HY-P99249 | Vonlerolizumab |
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models.
Species: Human |
|
/
|
| HY-P10927 | BRP |
BRP is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP is applicable to obesity-related research.
|
|
/
|
| HY-W016445 | D-Glucamine, 98% |
D-Glucamine, 98% (1-Amino-1-deoxy-D-glucitol, 98%) is an amino sugar derivative that serves as an excipient in pharmaceutical formulations. D-Glucamine, 98% also acts as a substrate for studies investigating sugar transporter pathways
|
|
/
|
| HY-W015777 | 4-Methoxybenzyl alcohol |
4-Methoxybenzyl alcohol (P-Methoxy-benzyl alcoho; (4-Methoxyphenyl) methanol) is a naturally derived volatile aromatic compound. 4-Methoxybenzyl alcohol upregulates the phosphorylation level of PI3K/Akt pathway proteins, downregulates the expression of pro-inflammatory factors, increases the content of tight junction proteins occludin and claudin-5, and alleviates structural damage to the blood-brain barrier. 4-Methoxybenzyl alcohol improves the decrease in viability and NO level of cerebral microvascular endothelial cells induced by oxygen-glucose deprivation/reperfusion, and reduces the release of lactate dehydrogenase. 4-Methoxybenzyl alcohol serves as a substrate in the two-phase persulfate-mediated electro-oxidation system, where it is directionally oxidized to p-anisaldehyde. 4-Methoxybenzyl alcohol acts as a substrate for wild-type fungal aryl alcohol oxidase. 4-Methoxybenzyl alcohol can be used in studies related to ischemic stroke, as well as in research across various fields such as chemical synthesis, including the synthesis of fragrances and flavorings.
|
|
/
|
| HY-W009154 | 3,6-Dibromocarbazole |
3,6-Dibromocarbazole is a glucocorticoid receptor (GR) inhibitor and Environmental pollutant. 3,6-Dibromocarbazole induces abnormal development of zebrafish embryos and disrupts the neurohormonal function of the hypothalamic-pituitary-adrenal axis in zebrafish larvae. 3,6-Dibromocarbazole increases the α-diversity of soil bacteria, alters community structure, enhances interspecific competition, regulates metabolic functions, and changes the abundance of genes related to nitrogen fixation, nitrification and carbon cycling. 3,6-Dibromocarbazole exerts endocrine-disrupting potential by interfering with the gluconeogenesis pathway.
|
|
/
|
| HY-D2836 | FITC-HA (MW 1000000) |
FITC-HA (MW 1000000) is hyaluronic acid (HA) (HY-B0633A) labeled with FITC (HY-66019). FITC-HA retains the ability of HA to bind to receptors (such as CD44) and form extracellular matrices, while it can be detected by fluorescence microscopy or flow cytometry for tracing the localization, binding, internalization and metabolic pathways of HA in cells, tissues or living organisms (Ex/Em ≈ 490/520 nM).
|
|
/
|
| HY-P10227 | Xelafaslatide |
Xelafaslatide (ONL-1204) is a Fas receptor antagonist. Xelafaslatide blocks the Fas receptor signaling pathway and inhibits downstream apoptosis and inflammatory pathways. Xelafaslatide suppresses neuroinflammation and microglial activation in glaucoma models, protects retinal ganglion cells and prevents axonal degeneration. Xelafaslatide is applicable to relevant research on glaucoma.
|
Fatty Acid Synthase (FASN)
Apoptosis
Interleukin Related
Toll-like Receptor (TLR)
NOD-like Receptor (NLR)
Caspase
|
/
|
| HY-P990025 | Empasiprubart |
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models.
Species: Human |
|
/
|
| HY-123051 | Ac-WLA-AMC |
Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate.
|
|
/
|
| HY-D1705 | Ac-ANW-AMC |
Ac-ANW-AMC is a fluorogenic substrate for immunoproteasome. Ac-ANW-AMC can be used to measure β5i activity (Ex=345 nm, Em=445 nm).
|
|
/
|
| HY-D0172 | Tetrabutylammonium bromide |
Tetrabutylammonium bromide is an organic ammonium compound, which is often used in catalytic reactions and separation and purification processes. It has a significant catalytic effect in some organic synthesis reactions, and can be used as a surfactant, stabilizer and antibacterial agent, etc. In addition, in some laboratory studies, this compound has also been used as an ion exchanger, solvent extractant, etc.
|
|
/
|
| HY-157839 | PROTAC α-Synuclein/Tau degrader 1 |
PROTAC α-Synuclein/Tau degrader 1 is a blood-brain barrier-penetrant dual PROTAC degrader of α-synuclein (α-Syn) and tau, with DC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 binds to α-Syn and tau PFF, with KDs of 0.47 and 2.78 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 exhibits degradation effect mediated by the ubiquitin-proteasome system (UPS). PROTAC α-Synuclein/Tau degrader 6 can be used for the study of Parkinson’s disease (PD) (Pink: α-Synuclein/Tau ligand (HY-151035); Blue: CRBN ligase ligand (HY-14658); Black: Linker (HY-128803)).
|
|
/
|
| HY-P99405 | Prasinezumab |
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research.
Species: Human |
|
/
|
| HY-116956 | D-Erythrose (50%w/w in water) |
D-Erythrose is a four-carbon sugar classified as an aldose. D-Erythrose has unique chemical properties that make it an important intermediate in various metabolic pathways, especially in the biosynthesis of amino acids and nucleotides. It also plays a role in the pentose phosphate pathway, which generates reducing equivalents for biosynthetic reactions and cellular defense against oxidative damage.
|
|
/
|
| HY-P9990 | Litifilimab |
Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody targeting BDCA2. Litifilimab induces internalization of BDCA2 receptors on the membrane of plasmacytoid dendritic cells, inhibits the TLR7/TLR9 signaling pathway, and suppresses the production of type I interferons. Litifilimab can be used in the research of systemic and cutaneous lupus erythematosus.
Species: Human |
|
/
|
| HY-P99965 | Crovalimab |
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.
Species: Human |
|
/
|
| HY-P99415 | Abelacimab |
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies.
Species: Human |
|
/
|
| HY-126389 | Chitin, from crab carapace (powder),biomedical research grade |
Chitin, from crab carapace (powder),biomedical research grade is a long-chain polymer of N-acetylglucosamine with β-(1-4) linkages. Chitin, from crab carapace (powder),biomedical research grade is found in the exoskeleton of crabs. Chitin, from crab carapace (powder),biomedical research grade inhibits the activation of NF-κB p65, alters the translocation of NF-κB p65 to the nucleus, and interacts with the cell wall of Candida species. Chitin, from crab carapace (powder),biomedical research grade exerts antifungal and anti-inflammatory effects. Chitin, from crab carapace (powder),biomedical research grade can be used in the research of gastric ulcer and candidiasis.
Source: Holotrichia parallela |
|
/
|
| HY-Y0006 | XPhos |
XPhos is a dual aryl monophosphine ligand. XPhos is an efficient and stable palladium catalytic ligand. XPhos can be used for amination of aryl sulfonate esters.
|
|
/
|
| HY-P71502 | Exopolyphosphatase/PPX Protein, E.coli (His) |
Exopolyphosphatase/PPX protein, a key enzyme, degrades inorganic polyphosphates (polyP) by catalyzing the processive release of orthophosphate. This activity is crucial for regulating cellular polyP levels and is implicated in various biological processes. The protein's role in polyP degradation contributes to maintaining phosphate homeostasis and is integral to the intricate network of cellular processes involving polyP. Exopolyphosphatase/PPX Protein, E.coli (His) is the recombinant E. coli-derived Exopolyphosphatase/PPX protein, expressed by E. coli , with N-6*His labeled tag.
Species: E.coli; Source: E. coli |
|
/
|
| HY-P701068 | PKA/PRKACA Protein, Canine (His) |
PKA/PRKACA Protein, Canine (His) is the recombinant canine-derived PKA/PRKACA protein, expressed by E. coli, with N-His labeled tag.
Species: Canine; Source: E. coli |
|
/
|
| HY-P701753 | PKA/PRKACA Protein, Human (Active, sf9, GST) |
PKACα protein is a key kinase that phosphorylates a variety of substrates, including CDC25B, ABL1, NFKB1, and VASP, affecting a variety of cellular processes, such as cell cycle progression, platelet regulation, and adipogenic differentiation. It also negatively regulates mTORC1 through RPTOR phosphorylation, thereby modulating signaling networks. PKA/PRKACA Protein, Human (sf9, GST) is the recombinant human-derived PKACα protein, expressed by sf9 insect cells , with GST tagged.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P702637 | PRKACB Protein, Human (Active, sf9) |
PRKACB Protein, Human (sf9) is the recombinant human-derived PRKACB, expressed by Sf9 insect cells , with tag Free labeled tag. ,
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P75701 | DDOST Protein, Human |
DDOST is a key subunit of the oligosaccharyltransferase (OST) complex, which catalyzes the initial glycan transfer during protein N-glycosylation. This co-translational process begins with the transfer of defined glycans to asparagine residues in the nascent polypeptide chain. DDOST Protein, Human is the recombinant human-derived DDOST protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P71103 | PRKAR1A Protein, Human (HEK293, His) |
PRKAR1A protein is a regulatory subunit of cAMP-dependent protein kinase and is critical for cAMP signaling. Upon activation by cAMP, it releases two catalytic monomers and a regulatory dimer from the inactive holoenzyme. PRKAR1A Protein, Human (HEK293, His) is the recombinant human-derived PRKAR1A protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P702638 | PRKACG Protein, Human (Active, sf9) |
PRKACG Protein, Human (sf9) is the recombinant human-derived PRKACG, expressed by Sf9 insect cells , with tag Free labeled tag. ,
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P71516 | Exopolyphosphatase/PPX Protein, E.coli (His-SUMO) |
Exopolyphosphatase/PPX proteins are dedicated to inorganic polyphosphate (polyP) degradation, expertly releasing orthophosphate from polyphosphate termini in a sustained manner. It shows a strong preference for long-chain polyphosphates, with moderate affinity for shorter sizes (approximately 15 residues). Exopolyphosphatase/PPX Protein, E.coli (His-SUMO) is the recombinant E. coli-derived Exopolyphosphatase/PPX protein, expressed by E. coli , with N-His, N-SUMO labeled tag.
Species: E.coli; Source: E. coli |
|
/
|
| HY-P75982 | PRKAR1A Protein, Mouse (sf9, His) |
PRKAR1A protein is a regulatory subunit of cAMP-dependent protein kinase that mediates cellular responses to cAMP signaling.The inactive holoenzyme has two regulatory chains and two catalytic chains.PRKAR1A Protein, Mouse (sf9, His) is the recombinant mouse-derived PRKAR1A protein, expressed by Sf9 insect cells , with C-His labeled tag.
Species: Mouse; Source: Sf9 insect cells |
|
/
|
| HY-P700578 | PKLR Protein, Rat (P. pastoris, His) |
The PKLR protein is a pyruvate kinase that plays a critical role in glycolysis, converting phosphoenolpyruvate to pyruvate and producing ATP.As a key enzyme, PKLR mediates the final steps of glycolysis, contributing to energy production.PKLR Protein, Rat (P.pastoris, His) is the recombinant rat-derived PKLR protein, expressed by P.pastoris , with N-6*His labeled tag.
Species: Rat; Source: P. pastoris |
|
/
|
| HY-P704016 | EIF2AK2 Protein, Human (Active, sf9, GST) |
The EIF2AK2 protein is an interferon-inducing kinase that initiates the innate immune response against viral infection. It phosphorylates eIF-2-α, activating the integrated stress response, inhibiting overall protein synthesis and favoring ISR-specific mRNAs such as ATF4. EIF2AK2 Protein, Human (Active, sf9, GST) is the recombinant human-derived EIF2AK2 protein, expressed by Sf9 insect cells, with N-GST labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P705862 | PKA/PRKACA Protein, Human (K48R, L96Q, M121L, V124A, Q182K, T184A) |
Species: Human; Source: E. coli |
|
/
|
| HY-P705863 | PRKACA-DNAJB1 Protein, Human (sf9, His-GST) |
Species: Human; Source: sf9 insect cells |
|
/
|
| HY-P81127 | PKA alpha+beta Antibody |
|
/
|
|
| HY-P81299A | Phospho-PKR (Thr446) Antibody (YA1026) |
Phospho-PKR (Thr446) Antibody (YA1026) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-PKR (Thr446).
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P80283 | PKR Antibody (YA124) |
PKR Antibody (YA124) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PKR.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P81270 | DNA PKcs Antibody (YA957) |
DNA PKcs Antibody (YA957) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to DNA PKcs.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P84479 | NF-κB p65 Antibody (YA4176) |
|
/
|
|
| HY-P80104 | DNA PKcs Antibody (YA782) |
DNA PKcs Antibody (YA782) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to DNA PKcs.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P81270B | DNA PKcs Antibody (YA959) |
DNA PKcs Antibody (YA959) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DNA PKcs.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P82002 | Proteasome 20S LMP2 Antibody (YA1747) |
Proteasome 20S LMP2 Antibody (YA1747) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Proteasome 20S LMP2.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P80876 | Proteasome 20S LMP7 Antibody (YA684) |
Proteasome 20S LMP7 Antibody (YA684) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Proteasome 20S LMP7.
Host: Mouse; Reactivity: Human, Rat |
|
/
|
| HY-P80429 | PKA R2/PKR2 Antibody (YA132) |
|
/
|
|
| HY-P86373 | NF-κB1 p105/p50 Antibody (YA6065) |
NF-κB1 p105/p50 Antibody (YA6065) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NF-κB1 p105/p50.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P80876A | Proteasome 20S LMP7 Antibody (YA684)(PBS only) |
Proteasome 20S LMP7 Antibody (YA684) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Proteasome 20S LMP7.
Host: Mouse; Reactivity: Human, Rat |
|
/
|
| HY-P81270A | DNA PKcs Antibody (YA958) |
DNA PKcs Antibody (YA958) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to DNA PKcs.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P81299 | Phospho-PKR (Thr451) Antibody (YA1025) |
Phospho-PKR (Thr451) Antibody (YA1025) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-PKR (Thr451).
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P82002A | Proteasome 20S LMP2 Antibody (YA1747)(PBS only) |
Proteasome 20S LMP2 Antibody (YA1747) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Proteasome 20S LMP2.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P82022 | PSMB10 Antibody (YA1767) |
PSMB10 Antibody (YA1767) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PSMB10.
Host: Rabbit; Reactivity: Human, Rat |
|
/
|
| HY-P82022A | PSMB10 Antibody (YA1767)(PBS only) |
PSMB10 Antibody (YA1767) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PSMB10.
Host: Rabbit; Reactivity: Human, Rat |
|
/
|
| HY-P85261 | Proteasome 20S LMP7 Antibody (YA4953) |
Proteasome 20S LMP7 Antibody (YA4953) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Proteasome 20S LMP7.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P85500 | Protein Phosphatase 4C Antibody (YA5192) |
Protein Phosphatase 4C Antibody (YA5192) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Protein Phosphatase 4C.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P85517 | PP2A alpha + beta Antibody (YA5209) |
|
/
|
|
| HY-P87649 | PRKRA Antibody (YA7333) |
PRKRA Antibody (YA7333) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PRKRA.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P88159 | PKLR Antibody (YA7843) |
PKLR Antibody (YA7843) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PKLR.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P88159A | PKLR Antibody (YA7843)(PBS only) |
PKLR Antibody (YA7843) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PKLR.
Host: Mouse; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P810621 | Phospho-PKA alpha/beta/gamma (catalytic subunit) (Thr197) Antibody (YA9883) |
Phospho-PKA alpha/beta/gamma (catalytic subunit) (Thr197) Antibody (YA9883) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-PKA alpha/beta/gamma (catalytic subunit) (Thr197).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P81270AA | DNA PKcs Antibody (YA958)(PBS only) |
DNA PKcs Antibody (YA958) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to DNA PKcs.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P81299AA | Phospho-PKR (Thr451) Antibody (YA1025) (PBS only) |
Phospho-PKR (Thr451) Antibody (YA1025) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-PKR (Thr451).
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P84479A | NF-κB p65 Antibody (YA4176)(PBS only) |
|
/
|
|
| HY-P86157 | PKR Antibody (YA5849) |
PKR Antibody (YA5849) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PKR.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P86492 | NF-κB p65 Antibody (YA6184) |
|
/
|
|
| HY-P86687 | NF-KB p65 Antibody (YA6379) |
NF-KB p65 Antibody (YA6379) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NF-KB p65.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P87910 | Phospho-NF-κB p65 (Ser536) Antibody (YA7595) |
Phospho-NF-κB p65 (Ser536) Antibody (YA7595) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-NF-κB p65 (Ser536).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-K1055 | Kanamycin sulfate (100x), Sterile |
Kanamycin sulfate is an aminoglycoside antibiotic purified from Streptomyces kanamyceticus. It acts by binding to the 30S subunit of the bacterial ribosome and inhibiting protein synthesis in susceptible bacteria. |
|
/
|
| HY-K3017 | HT Supplement (50×) |
MCE HT Supplement (50×) is a liquid mixture of hypoxanthine (5 mM) and thymidine (0.8 mM), and can be added to cell culture medium as an additive for the DNA salvage synthesis pathway. The 10 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base. |
|
/
|
| HY-K6009 | Basement Membrane Matrix GFR&HC |
MCE Basement Membrane Matrix GFR&HC (Growth Factor Reduced, High Concentration) is primarily composed of natural basement membrane matrix extracted from mouse tumors, is suitable for cell cultures that need to reduce growth factor induction and studies related to growth factors, signaling pathways, etc. |
|
/
|
| HY-K6021 | CEPT Cocktail Plus (1000×) |
MCE CEPT Cocktail Plus (1000×) is a composite supplement specifically formulated for pluripotent stem cell culture. Through synergistic effects, it inhibits oxidative damage, blocks apoptotic pathways, and regulates protein translation, significantly reducing cellular stress levels through multiple targets. This dramatically improves the survival rate and cloning efficiency of pluripotent stem cells. |
|
/
|
| HY-K6301 | Human iPSC/ESC Cortical Brain Organoid Induction Differentiation Kit |
MCE Human iPSC/ESC Cortical Brain Organoid Induction Differentiation Kit is a standardized culture system specifically designed to recapitulate the developmental processes and functional features of the human cerebral cortex through forebrain ventralization-based signaling regulation. By sequentially activating the Wnt/β-catenin pathway and gradually inhibiting BMP/Smad signaling, this system efficiently drives human pluripotent stem cells (PSC) to differentiate into high-purity glutamatergic neurons (VGLUT1/2+ > 85%), while simultaneously promoting the formation of Pax6+/BLBP+ radial glial cells that establish a biomimetic ventricular-zone–like structure. |
|
/
|
| HY-K6303 | Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit |
MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies. |
|
/
|
Targets/Pathways
Brochures




































.jpg)


























































































































































































